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Masennuslääkkeet ovat keskeinen depression hoitomuoto yleislääketieteessä ja psykiatriassa. 
Psykiatri Joanna Moncrieff ja psykologi Irving Kirsch esittävät plaseboargumentin 
kyseenalaistaakseen niiden tehon.  
 
Yleisen plaseboargumentin mukaan masennuslääkkeiden tehoero lumelääkkeeseen verrattuna on 
vaatimaton. Moncrieff ja Kirsch pyrkivät myös osoittamaan, että tilastollisesti merkitsevät erot 
masennus- ja lumelääkkeen välillä ovat kliinisesti merkityksettömiä. He myös pyrkivät 
osoittamaan, että lääkkeillä ei ole todellista farmakologista vaikutusta masennukseen. Tätä osaa 
argumentista kutsun “aktiivisen plasebon” argumentiksi. 
 
Analysoin työssäni Myth or cure? The placebo argument in the contemporary debate on the 
pharmacological treatment of depression kriittisesti Kirschin ja Moncrieffin argumentin osa-alueet. 
Peilaan heidän argumentaatiotaan psykiatrian valtavirtaan, jota edustaa depression Käypä hoito -
suositus.  
 
Työn tavoite on selvittää, onnistuvatko Moncrieff ja Kirsch osoittamaan keskeinen masennuksen 
hoitomuoto tehottomaksi. 
 
Yleinen plaseboargumentti pitää käyttämäni materiaalin perusteella paikkansa, mutta sekä 
kriitikkojen että Käypä hoito -suosituksen esittämiä väitteitä masennuslääkkeiden tehon kliinisestä 
merkityksestä on mahdotonta arvioida. Kriitikkojen “aktiivinen plasebo” –argumentti epäonnistuu, 
koska se on ristiriidassa heidän käyttämiensä tutkimusten kanssa.  
 
 
 
Contents 
Introduction 1 
1. “Antidepressants are effective for all severities of 
depression”: the guidelines 
6 
1.1 Short-term treatment 6 
1.2 Long-term treatment 18 
2. Placebo: the Kirsch-Moncrieff argument 23 
2.1 Moncrieff on antidepressants versus placebo 23 
2.1.1 Short-term treatment 23 
2.1.2 Severity 25 
2.1.3 Long-term treatment 30 
2.2 The placebo argument: Kirsch 33 
3. “Active placebo” 37 
3.1 “Active placebo”: Kirsch 37 
3.2 Moncrieff on antidepressants versus “active placebo” 41 
3.3 Moncrieff on antidepressants versus other drugs 42 
4. Assessing the Kirsch-Moncrieff Argument 44 
4.1 Short-term treatment 44 
4.2 Severity 45 
4.3 Long-term treatment 47 
4.4 “Active placebo” 48 
Conclusion 52 
Bibliography 55 
1 
Introduction 
Depression is one of the leading causes of morbidity both in Finland and worldwide.1 In current 
treatment guidelines, pharmacological treatment is presented as central, especially in cases of 
moderate or severe depression.2 The drugs of first choice for depression are the selective serotonin 
reuptake inhibitors (SSRIs). Other newer drugs, such as the serotonin-noradrenaline reuptake 
inhibitors (SNRIs), are also possibilities for first-line treatment of depression. The tricyclic 
antidepressants (TCAs), the first choice drug treatment before the advent of the SSRIs, are still 
widely in use, and are possibilities for patients whose depression does not respond to SSRI or SNRI 
treatment.  
Psychiatrists claim that two thirds of depressed patients taking antidepressants experience a 
significant amelioration of symptoms, whilst one third of patients taking placebo experience the 
same effect.3 In the era of evidence-based medicine, the ultimate justification for the use of 
antidepressants in treating depressed patients is this apparent superiority compared to placebo in 
randomized controlled trials. 
 In recent years, critics have challenged the evidence on the effectiveness of antidepressants. 
A number of meta-analyses, which have shown little difference between active drugs and placebo, 
have been published.4 Some critics have questioned whether antidepressants have any specific 
pharmacological effect on depression at all. This essay explores these critiques of the evidence base 
of antidepressant treatment. I will focus on the work of two prominent critics: Irving Kirsch and 
Joanna Moncrieff.  
Psychologist Irving Kirsch, currently Director of the Program in Placebo Studies and 
lecturer at Harvard Medical School, has co-authored a number of meta-analyses investigating drug 
and placebo responses in depression. He has also written a book intended for non-specialist readers, 
The Emperor’s New Drugs, which outlines his thinking on antidepressants.5 Kirsch states that he 
                                                
I would like to thank Professor Raimo Puustinen for patient supervision of this project, and insightful 
comments on numerous versions of the manuscript. I would also like to thank psychologist Samuli 
Kangaslampi for incisive comments on the manuscript and especially for clarifying some of the statistics in 
the studies discussed here. 
1 Kessler RC & Bromet EJ. The Epidemiology of Depression Across Cultures. Annu Rev Public Health 
2013; 34:119-138. Lönnqvist J, Henriksson M, Marttunen M et al. Psykiatria. Helsinki: Kustannus Oy 
Duodecim 2011. 
2 Depression. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and 
the Finnish Psychiatric Association. Helsinki: The Finnish Medical Society Duodecim, 2016. 
3 ibid. 
4 Eg. Kirsch I, Moore TJ, Scoboria A et al. The Emperor’s New Drugs: An Analysis of Antidepressant 
Medication Data Submitted to the U.S. Food and Drug Administration. Prevention & Treatment 2002. I was 
only able to obtain an online copy without the original page numbers, so the numbers given below refer only 
to pages within this single article.  
5 Kirsch I. The Emperor’s New Drugs: Exploding the Antidepressant Myth. London: The Bodley Head 2009. 
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came to be interested in the efficacy of antidepressants through his original interest in the placebo 
response in depression. He approaches the issues covered in this essay based on the meta-analyses 
he has co-authored. In Finland, the debate in the media over the efficacy of antidepressants has 
largely arisen from news coverage of Kirsch’s meta-analyses. 
Joanna Moncrieff is a practicing psychiatrist based in the UK. Her project is a critique of 
contemporary psychiatry as a whole, and is by no means limited to arguing that antidepressants are 
no better than placebo in treating depression.6 She questions the concept of mental illness in 
contemporary psychiatry, arguing that psychiatry is fundamentally political. Invoking Marx and 
Foucault, she defines her task as uncovering the interests that have been at work in establishing 
what she calls the “disease-centered” model of psychiatric disorder.7 She argues that psychiatry 
conceptualizes the disorders it diagnoses as “chemical imbalances” in the brain, and that psychiatry 
understands the pharmacological agents it employs as working by correcting these imbalances.8 Her 
central thesis is that this understanding of psychiatric disorder or its treatment is not based on strong 
evidence, but has become entrenched in psychiatry because it serves powerful interests.9  
She argues that the disease-centered model should be replaced with what she calls the 
“drug-centered” one. This model acknowledges that psychiatric drugs do not have any specific 
effect on some underlying biological pathology, but they do have unspecific effects, such as 
sedation, that can be useful for relieving the distress of some depressed patients.10  
Despite their differing foci, Kirsch and Moncrieff share their major arguments, and some of 
their evidence. Exploring the work of both critics provides a more complete picture of these 
arguments.  
The central thrust of their critique is what I call the placebo argument. In short, it is the 
claim that antidepressants are not significantly more effective than placebo, that differences 
between active drugs and placebo in antidepressant trials are very small. In other words, it states 
that the clinical improvement seen in patients taking antidepressants is almost completely explained 
by a non-specific response that occurs with placebo treatment as well.  
This is the general claim that the critics make. There are two more specific claims, which 
are aspects of the general argument. The first, which I call the clinical relevance argument, is that, 
even though there are statistically significant differences between active drug and placebo in 
antidepressant trials, these are so small as to be clinically meaningless. Even though the critics 
                                                
6 Moncrieff J. The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment. Houndmills: 
Palgrave Macmillan 2008.  
7 ibid., 13. 
8 ibid., 9-11. 
9 ibid., 13. 
10 ibid., 14-29. 
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emphasize this, they reference such limited material on this issue that an in-depth analysis is not 
possible here. I return to clinical relevance in the Conclusion. 
The second claim attempts to explain the small differences between drug and placebo. This 
is the “active placebo” argument, which states that the statistical superiority of drug over placebo in 
antidepressant trials is not due to a true pharmacological effect, but rather to patients breaking blind, 
as the more frequent side effects of the active drug lead patients to realize that they are receiving 
active drug treatment, boosting their expectations of recovery.  
The aim of this essay is to consider to what extent the critics hit the mark. Are they able to 
undermine the basis of the contemporary approach to treating depression, or are their arguments 
straw men, misrepresenting the way psychiatry conceptualizes these key treatments?  
The conventional best practice of treating depression will be represented by the treatment 
guidelines (hereafter “guidelines”) published by the Finnish Medical Society Duodecim.11 Doctors 
routinely refer to them to guide their clinical decision-making; they are also a major source for 
teaching medical students. The guidelines also explicitly refer to the debate on the efficacy of 
antidepressants. For the purposes of this study, they are sufficient representatives of mainstream 
psychiatry.  
The guidelines cover many aspects of the diagnosis and treatment of depression. I only 
discuss the evidence summaries for short- and long-term antidepressant drug treatment for 
depression, authored by Professor of Psychiatry Erkki Isometsä, since this essay is focused on the 
debate on the effectiveness of such drugs. All references to the guidelines, unless otherwise 
specified, are to these evidence summaries appended to the full guideline.12 
This essay is organized around the three major aspects of the critics’ placebo argument. The 
material in different sections will inevitably overlap, as the different aspects of the overall argument 
are closely connected. In the first section, I analyze arguments on the effectiveness of 
antidepressants compared to placebo. I first critically examine the evidence that the guidelines draw 
on to support the view that antidepressants are effective for short- and long-term treatment of 
depression. In the next section, I examine the evidence that Moncrieff uses to dispute such claims. I 
consider the evidence on three aspects of her argument: antidepressant versus placebo for short-
term treatment, the effect of the initial severity of depression on drug/placebo differences, and drug 
                                                
11 Duodecim 2016. 
12 As far as I can tell, the evidence summaries are only available online, so it is not possible to be as accurate 
with references to them as I have sought to be with references to other materials. I will refer to them with 
”Duodecim 2016”. In other cases, I have tried to include page numbers for the exact locations of arguments 
and data, so the reader can easily check whether I have presented the material fairly. The evidence 
summaries are freely available online in Finnish. Acute treatment: 
http://kaypahoito.fi/web/kh/suositukset/suositus?id=nak04327&suositusid=hoi50023. Long-term treatment: 
http://kaypahoito.fi/web/kh/suositukset/suositus?id=nak04347&suositusid=hoi50023 and 
http://kaypahoito.fi/web/kh/suositukset/suositus?id=nak04350&suositusid=hoi50023  
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versus placebo for long-term treatment. In the final part of this section I discuss the evidence that 
Kirsch presents for his version of this aspect of the placebo argument. The focus is on Kirsch’s own 
meta-analyses. 
In the next section, I discuss the “active placebo” aspect of the overall argument. The critics 
present two “active placebo” claims. The first is that double-blind antidepressant trials are not truly 
blind, because the more frequent incidence of side effects in the drug treatment group enables 
patients to guess they are receiving active treatment, changing expectations of recovery. The second 
is that other pharmacological agents, which are not considered specific antidepressants, show 
superiority over placebo in clinical trials. The idea is that like antidepressants, these drugs act as 
“active placebos”, producing side effects, which enable patients to guess which treatment group 
they have been assigned to.  
Throughout, I focus my discussion primarily on the SSRIs, SNRIs, and other newer 
pharmacological agents widely used today. There is inevitably some overlap with older drugs, 
particularly TCAs, since many of the studies discussed include these older drugs. Joanna Moncrieff 
in particular bases much of her argument on older TCA trials. Likewise, there is some overlap with 
other forms of depression – psychotic depression and bipolar disorder are discussed in passing – but 
the focus is on major depressive disorder. 
There are three important aspects of the critics’ argument that it is not possible to discuss 
systematically in the main body of this essay – I will outline these issues in the Conclusion. The 
first is the question of clinical relevance. It is crucial to the critical argument, but there is very 
limited material for assessing it, and it is not systematically addressed by the guidelines. The second 
one is the question of how the use of antidepressants affects depression outcome in real-world 
settings. The third is the critics’ conceptual argument: that depression is not a malfunction of the 
brain’s monoamine system, and that therefore, the notion that depression can be cured by using 
drugs correcting an imbalance in that system is a myth.  
Pharmacological treatment is central to contemporary psychiatry and to the treatment of 
psychiatric disorders in general practice. Furthermore, depression is common and disabling; 
effective treatments are essential. If the critics are right, the implications for both psychiatry and 
general practice are vast. Is the widespread prescribing of antidepressants justified? Why does 
clinical experience seem to confirm the effectiveness of antidepressants? Why do so many patients 
respond to placebo in antidepressant trials? How big should the drug/placebo difference in clinical 
trials be to justify the use of antidepressants? How should we help people suffering from 
depression? What does the effectiveness or lack thereof of antidepressants tell us about the etiology 
of depression? There are a plethora of issues for clinical trials, meta-analyses, and more conceptual 
research to address in the territory opened up by this debate. 
5 
In conclusion, I attempt to draw some implications from the evidence and arguments 
covered in this essay for the individual clinician facing the depressed patient, who is desperate for 
alleviation of their suffering. Is prescribing an antidepressant a reasonable way of attempting to ease 
their distress?  
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1. “Antidepressants are effective for all severities of depression”: the guidelines 
The guidelines note that there has been critical debate on how clinically relevant drug/placebo 
differences are, but argue that the evidence is unequivocal: it shows that antidepressants are 
effective in all severities of depression.13 The guidelines present evidence for both acute-phase and 
long-term treatment.  In this section, I critically discuss the way that the guidelines present the 
findings and conclusions of these meta-analyses.  
 The guidelines cite eleven meta-analyses in support of the conclusion that antidepressants 
are effective for acute-phase treatment. I omit two of these studies: the first one because it concerns 
reboxetine, which is no longer in use, and the second one because it is a study of dysthymia rather 
than major depressive disorder. The guidelines further discuss four meta-analyses in support of the 
conclusion that antidepressants are effective for preventing depression relapse over the long term; I 
turn to these in section 1.2. 
 
1.1 Short-term treatment 
The first meta-analysis cited by the guidelines, Turner et al. 2008, focuses on the effects of 
publication bias by comparing published and unpublished double-blind placebo-controlled trials for 
twelve antidepressants.14 The unpublished trials are drawn from studies submitted to the Food and 
Drug Administration (FDA) in the United States by industry for approval of the antidepressants. 
Even though drug companies are under no obligation to publish the results of all the trials they run, 
the FDA does require them to submit all the trials they have conducted in order to gain approval for 
a new drug. Included in the meta-analysis are 74 studies including 12 564 patients submitted to the 
FDA for the approval of the following antidepressants: bupropion, citalopram, duloxetine, 
escitalopram, fluoxetine, mirtazapine, nefazodone, paroxetine, sertraline, and venlafaxine.15 Of 
these, citalopram, escitalopram, fluoxetine, paroxetine and sertraline are SSRIs. Nefazodone has 
been withdrawn from the market. 
The researchers categorized the studies based on whether the FDA considered the trial result 
positive or negative. Of the published studies, 94% were deemed positive by the FDA, whereas 
when the unpublished studies are included, only 51% of all trials show superiority over placebo.16 
As the guidelines point out, the antidepressants fared worse when all the studies were included, but 
                                                
13 Duodecim 2016. 
14 Turner EH, Matthews AM, Linardatos E et al. Selective publication of antidepressant trials and its 
influence on apparent efficacy. The New England Journal of Medicine 2008; 358: 252-260. For brevity, I 
will only use the first author’s name and year of publication when referring to a study in the main text. 
15 ibid., 258, Figure 3. 
16 ibid., 255. 
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they were still all superior to placebo.17 The overall Hedges’s g effect size of all the antidepressants 
is 32 per cent higher when only published trials are included.18  
The second meta-analysis cited by the guidelines is co-authored by Irving Kirsch, one of the 
leading critics of antidepressant use.19 This study also attempts to work around publication bias by 
utilizing trials submitted to the FDA. The researchers used the Freedom of Information Act to 
request the data submitted to the FDA for the approval of six antidepressants: fluoxetine, 
venlafaxine, nefazodone, paroxetine, sertraline and citalopram. In total, the meta-analysis included 
35 clinical trials. The meta-analysis focused on investigating the effects that the initial severity of 
depression has on patients’ response to antidepressants. Severity was rated on the Hamilton 
depression scale.  
Overall, the study found that patients taking antidepressants improved by a mean of 9.60 
points on the Hamilton scale, and patients taking placebo improved by 7.80 points. In other words, 
the mean difference between drug and placebo was 1.80.20 The statistical analysis shows that the 
superiority of drug over placebo grows as the initial severity of depression rises. Partly this is 
because drug response improves as the initial Hamilton score rises, partly because placebo response 
diminishes as the initial Hamilton score grows.21  
In all but one of the trials the patients were very severely depressed. Thus, the one study 
including moderately depressed patients was deemed an outlier, and the researchers reran the 
statistical analysis with this one study excluded.22 In this analysis, the relationship of drug efficacy 
to initial severity of depression is flat. In other words, drug efficacy remains constant even as the 
initial severity of depression rises (within the very severe range). In this analysis, antidepressants 
are superior to placebo. Response to placebo in this analysis decreases as initial severity of 
depression rises.23 In summary, this meta-analysis shows that when the outlier study is excluded, 
drug efficacy is flat as initial depression becomes more severe, whereas placebo performs worse. It 
is not that drug response is better the more depressed the patient is but that they are less likely to 
respond to placebo.24  
The guidelines state that the study unequivocally shows the superiority of antidepressants 
over placebo. As we have seen, it is true that when the one outlier is excluded, the drugs outperform 
                                                
17 ibid., 259; Duodecim 2016. 
18 Turner, Matthews & Linardatos et al. 2008, 258. Of the SSRIs, sertraline fares the worst: its effect size is 
64% bigger when only published studies are included, dropping to 0.26 when unpublished studies are 
included. With paroxetine, the difference is the smallest: the effect size drops from 0.36 to 0.32. 
19 Kirsch I, Deacon BJ, Huedo-Medina TB et al. Initial severity and antidepressant benefits: a meta-analysis 
of data submitted to the Food and Drug Administration. PLos Med 2008; 5: 260-268. 
20 ibid., 263. 
21 ibid., 263. 
22 ibid., 263. 
23 ibid., 265, Figure 3. 
24 ibid., 266. 
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placebo. However, the guidelines also state that the difference between drug and placebo does not 
seem clinically significant in cases of mild depression, with a score of less than 20 points on the 
Hamilton scale cited as the criterion of mild depression. This is different from Kirsch et al.’s 
criterion: according to them, mild depression is indicated by a score of 8-13 on the Hamilton scale, 
and severe depression by a score of 19-22.25 Thus a score of less than 20 could be categorized as 
severe or moderate depression by Kirsch et al. 
Furthermore, as we have seen, there is only one study included in the meta-analysis where 
the mean initial severity of depression was less than 20 points on the Hamilton scale. In this 
fluoxetine trial, the baseline severity was 17 points, which would indicate moderate depression 
according to the criteria used by Kirsch et al. In other words, if we follow the criteria used by 
Kirsch and colleagues, no studies of mild depression were included in the meta-analysis. The 
guidelines claim that on the basis of this meta-analysis, the drug/placebo difference seems clinically 
insignificant in mild depression. It is difficult to see how this claim could be made, as it is not 
possible to say anything about mild depression on the basis of this study. 
The guidelines also seem to imply that even though the drug/placebo difference may not be 
clinically relevant for mild depression, it is clinically relevant for more severe depression, though 
this is not explicitly stated. This completely ignores Kirsch et al.’s central conclusion, which is that 
the drug/placebo difference reaches clinical significance only in the case of the most severely 
depressed patients. As noted, the average drug/placebo difference was 1.8 points on the Hamilton 
scale. The authors point out that the National Institute for Clinical Excellence (NICE) in the UK has 
adopted a 3-point difference as the threshold of clinical relevance.26 Excluding the outlier study, the 
researchers showed that for the most severely depressed patients, there is a difference between drug 
and placebo that is clinically relevant according to the NICE criteria.27 Note that whilst the 
guidelines imply that the drug/placebo difference is only clinically irrelevant in the case of mild 
depression, Kirsch et al.’s conclusion is that the difference reaches clinical relevance only in the 
case of the most severely depressed patients. 
 Melander et al. 2008 is the third meta-analysis cited by the guidelines.28 This study refers to 
Kirsch et al. 2008 and other studies which question the efficacy of antidepressants and poses the 
question: if antidepressants are not more effective than placebo in a clinically meaningful sense, 
why were they approved for sale by the authorities in the first place?29  
                                                
25 ibid., 266; Kirsch 2009, 31. 
26 Kirsch, Deacon & Huedo Medina et al. 2008, 266. 
27 ibid., 266. 
28 Melander H, Salmonson T, Abadie E et al. A regulatory Apologia - A review of placebo-controlled studies 
in regulatory submissions of new-generation antidepressants. European Neuropsychopharmacology 2008; 
18: 623-627. 
29 ibid., 624. 
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The authors note that the meta-analyses, which question the clinical relevance of 
antidepressant/placebo differences, focus on average differences in Hamilton scores between drug 
and placebo groups. They argue that this is an inadequate standard. They maintain that such group-
level differences in mean depression scores are useful for establishing the statistical significance of 
the drug effect, but that clinical relevance should be decided on the basis of the “percentage of 
patients achieving a clinically meaningful response”.30 The threshold of this clinically meaningful 
response is then defined as at least a 50% reduction in Hamilton score.31 No justification for this 
figure is given, though the authors do point out that it is widely used in antidepressant studies, and 
that, since a Hamilton score of at least 18 is required for inclusion in most trials, a patient would 
need to experience at least a nine point reduction to be counted a responder.32 The authors also note 
that this should be compared to the average absolute difference of around two points “usually 
observed”.33  
 The study included all the trials that had been submitted by industry for the approval of six 
SSRIs and two SNRIs for sale in Sweden. It included randomized placebo-controlled trials that 
lasted at least four weeks. In total, the study included 56 studies with 7374 patients. As the meta-
analysis is based on all studies submitted to the regulator for approval, the influence of publication 
bias should be minimal.34 
 The response rate for patients taking an active drug was 48%, and for patients taking 
placebo it was 32%.35 All the individual antidepressants were found to be superior to placebo. The 
difference in response rates for individual antidepressants versus placebo ranged from 13.5% to 
19.3%-units. No relationship between baseline severity of depression and response was found.36 
 The guidelines mention the results noted above, but they also claim that the meta-analysis 
covered all severities of depression, and showed the effectiveness of antidepressants in mild 
depression, as well.37 It is hard to understand this claim. The mean initial depression scores on the 
Hamilton scale ranged from 19.8 to 23.8, with an average score of 21.6. The range of individual 
scores varied from 17.6 to 28.4.38 In other words, the least depressed patient included in the meta-
analysis had a score of 17.6, and the most severely depressed patient had a score of 28.4. As noted 
above, the cut off point for mild depression that Kirsch uses is 13 and the one for moderate 
depression is 18. In the Hamilton questionnaire available on Duodecim’s Terveysportti portal, a 
                                                
30 ibid., 624. 
31 ibid., 624. 
32 ibid., 626. 
33 ibid,. 626. 
34 ibid., 626. 
35 ibid., 626. 
36 ibid., 625. 
37 Duodecim 2016. 
38 Melander, Salmonson & Abadie et al. 2008, 624, table 1. 
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database widely used by Finnish clinicians, the range for mild depression is 8-15 points, and severe 
depression is indicated by a score of over 15 points; this classification omits moderate depression. 
Regardless of the criteria used, it is clear that the Melander et al. 2008 meta-analysis does not 
include mildly depressed patients. Under the criteria Kirsch uses, the least depressed patient is 
moderately depressed, under the second criteria he or she is severely depressed. The guidelines’ 
assertion that Melander et al. 2008 shows antidepressants to be effective in mild depression is 
incorrect. 
The fourth meta-analysis cited in the guidelines looks at trials involving imipramine and 
paroxetine.39 Imipramine is a tricyclic antidepressant that is not in use in Finland, and paroxetine is 
an SSRI. The aim of the study is similar to Kirsch et al. 2008 discussed above: to assess the effect 
that the initial severity of depression has on the efficacy of drug and placebo. The authors refer to 
Kirsch et al. 2008 and note that this meta-analysis mostly included very severely depressed 
patients.40 Fournier et al. 2010 includes patients with lower scores on the Hamilton scale, including 
one trial of minor depressive disorder in the meta-analysis. One other important feature of the study 
design is that it excludes trials that include a placebo washout period. A placebo washout is used to 
exclude strong placebo responders before the trial starts. The authors argue that this potentially 
weakens response to placebo in the trial proper.41 
Six trials were included.42 Overall, the Cohen’s d effect size for patients with mild to 
moderate depression was 0.11, severe depression 0.17 and very severe depression 0.47. For these 
same groups, number-needed-to-treat values were 16, 11, and 4.43 Using the NICE criteria 
according to which the minimum threshold of clinical relevance is an improvement of three points 
on the Hamilton scale, the authors point out that the drug/placebo difference reaches clinical 
relevance when the initial severity of depression is 25 or higher on the Hamilton scale. In other 
words, the difference only becomes clinically relevant in the very severe range of depression. The 
other NICE criterion for clinical relevance is an effect size of over 0.50. Using this criterion, the 
authors point out that the drug/placebo difference reaches clinical relevance only when the initial 
severity of depression is 27 or greater on the Hamilton scale.44 The researchers reran the analysis 
whilst excluding the one study of minor depressive disorder; this did not change the threshold of 
clinical relevance.45 
                                                
39 Fournier JC, DeRubeis RJ, Hollon SD et al. Antidepressant drug effects and depression severity: A 
patient-level meta-analysis. JAMA 2010; 303: 47-53. 
40 ibid., 48. 
41 ibid., 48-49. 
42 ibid., 50. 
43 ibid., 51. 
44 ibid., 51. 
45 ibid., 51. 
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Fournier et al. 2010 concludes that antidepressants provide clinically relevant benefits only 
for severely depressed patients.46 The guidelines argue that this conclusion is not justified. They 
point out that a relatively small number of patients were included, that only six studies were 
included and that only two antidepressants were studied.47 This is the strongest critical argument 
made, but it ignores the reason for the limited number of trials. Fournier et al. 2010 points out that 
the majority of antidepressant trials are conducted with patients who are severely depressed, even 
though they do not represent the majority of patients in clinical practice.48  
The guidelines also state that Fournier et al. 2010 includes patients whose depression is less 
severe than the depression covered by the guidelines.49 It is difficult to understand this claim. The 
guidelines cover all severities of major depressive disorder, and explicitly state that antidepressants 
are superior to placebo even in mild depression. The claim that the patients in Fournier et al. 2010 
are not depressed enough is also curious because it specifies that these less severely depressed 
patients are in the 8-18 range on the Hamilton scale. However, the minimum cut off point for 
patients in the one trial on minor depressive disorder included by Fournier et al. 2010 is ten points 
on the Hamilton scale.50 All the other trials have a cut off point of 14 points or higher.51 
Furthermore, as noted, Fournier and colleagues reran the statistical analysis with the one trial of 
minor depressive disorder excluded, which did not change the threshold of clinical relevance.  
The next meta-analysis, Undurraga and Baldessarini 2012, includes 142 randomized 
placebo-controlled trials of 19 antidepressants approved for sale in the United States published 
between 1980-2011, with a total of 27 127 patients. 52 36.6% of the trials involved SSRIs, 26.8% 
tricyclic antidepressants, 9.9% atypical antidepressants, and 3.5% MAO inhibitors.53 The outcome 
measured is response, which is defined as a specific reduction in the depression score on the 
different scales used in the individual studies. The vast majority of the trials use some variation of 
the Hamilton scale. On that scale, response is defined as a reduction of at least 50%.54  
The meta-analysis showed the superiority of drugs over placebo: the overall drug/placebo 
pooled rate ratio for response was 1.42.55 The individual trials show consistent superiority of drug 
over placebo, as there is only one study in which there were more responders in the placebo group.56  
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This meta-analysis provides evidence for the claim in the guidelines that antidepressants, 
including SSRIs, are superior to placebo in the treatment of depression. However, a fundamental 
problem with this meta-analysis is that it makes no attempt to account for publication bias: only 
published trials are included,57 and over 97 per cent of them were funded by drug manufacturers.58 
Furthermore, the study does not differentiate outcomes based on the initial severity of depression. 
The authors note that their results are in line with other studies showing that drug/placebo 
differences are generally moderate.59 
 The next meta-analysis cited by the guidelines is Gibbons et al. 2012.60 It refers to both 
Turner et al. 2008 and Kirsch et al. 2008 discussed above in noting that recent studies have 
suggested that the superiority of antidepressants over placebo has been overstated.61 The authors 
argue that the sort of “vote counting” methodology used in Turner et al. 2008 in finding that the 
number of studies deemed positive by the FDA is markedly reduced when unpublished trials are 
included is inadequate for assessing clinical effectiveness.62 As an aside, it should be noted that 
Turner et al. 2008 makes no strong claims about the clinical effectiveness of antidepressants. That 
study is focused on the effect of publication bias, not on the question of whether drug/placebo 
differences are clinically relevant. The authors do note that including unpublished studies shows 
antidepressants to be less effective than a meta-analysis including only published trials, but that all 
the drugs were still superior to placebo, and they make no conclusions about clinical relevance.63 
Gibbons et al. 2012 also questions the methodology used by Kirsch and colleagues, arguing 
that patient level data is required to draw the conclusion made in that study. In other words, the 
authors maintain that using average study-level initial severity of depression instead of patient-level 
initial severity of depression is inadequate.64 
 The study includes patient-level data of placebo-controlled trials of fluoxetine conducted by 
Eli Lilly and venlafaxine trials conducted by Wyeth. For fluoxetine, 12 trials comprising 2 635 
patients were included.65 Venlafaxine IR (instant release) and ER (extended release) were studied 
separately. For venlafaxine IR, 11 trials with 2 421 patients, and for venlafaxine ER, 10 trials with 2 
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461 participants were included.66 The outcomes measured were change in the patient’s Hamilton 
score, response, and remission. Response was defined as a 50% or greater reduction in Hamilton 
score, and remission as a score of less than 8. All outcomes were measured at six weeks.67  
 For adult patients taking fluoxetine, the average reduction in their Hamilton score was 10.12 
points and for those taking placebo, it was 7.52 points, yielding a drug/placebo difference of 2.6 
points. The overall response rate for fluoxetine was 55.1% and for placebo 33.7%. The remission 
rate in the fluoxetine group was 45.8% and in the placebo group it was 30.2%.68 For adult patients 
taking venlafaxine ER, average reduction in Hamilton score was 12.39 versus 10.21 for placebo, for 
a difference of 2.18 points. For IR, the figures are 14.32, 10.71, and 3.61, respectively.69 
 No statistically significant effect of initial severity of depression on either absolute 
improvement or response was found for fluoxetine or either type of venlafaxine versus placebo.70 
 The authors argue that even though average reductions in the drug and placebo groups do 
not differ markedly from each other, this is “an enormous difference” from a public health 
perspective.71 They note that the difference in response rates between the fluoxetine and placebo 
groups means that one additional patient responds for every five patients treated with fluoxetine.72 
Likewise, the guidelines conclude that this study showed that active drugs were superior to placebo 
in mild, moderate and severe depression.  
 It should be noted that even though Gibbons and colleagues criticize Kirsch et al. 2008, and 
reach different conclusions, they reach those conclusions using different criteria. The NICE criteria 
for clinical relevance are not used. According to those criteria, the overall fluoxetine/placebo 
difference, 2.60 points on the Hamilton scale, is clinically irrelevant. Only venlafaxine IR reaches 
clinical relevance under these criteria, with an overall difference of 3.61 points. 
 It is difficult to assess the validity of this study, as no indication is given of exactly how 
depressed the patients included in the trials were. As noted in Fournier et al. 2010, most trials of 
antidepressants are conducted with patients who are quite significantly depressed. The range of 
initial depression scores is relevant because the study includes separate analyses of patients with 
lower and higher severities of depression. Furthermore, Gibbon et al. 2012 note that only 52.2% of 
patients had a Hamilton depression score in week six of their trials.73 As far as I can tell, the 
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assessment of patients at six weeks is based on a Bayes estimate of available data on the patient, 
even if they had dropped out prior to six weeks. The authors do not clarify this further.74  
 Taylor et al. 2014 is a meta-analysis of all published and unpublished short-term trials of the 
new antidepressant agomelatine. Agomelatine is a serotonin receptor (specifically 5HT2c) antagonist 
and an agonist of melatonergic MT1 and MT2 receptors. Thus, its mechanism of action is quite 
distinct from other antidepressants.  
The study included 20 trials with 7460 patients.75 Twelve trials compared agomelatine to 
placebo and thirteen studies compared agomelatine to established antidepressants (escitalopram, 
fluoxetine, sertraline, paroxetine, and venlafaxine).76  The risk of publication bias should be 
negligible, since the authors received data on all trials used for regulatory approval from the 
European Medicines Agency (EMA), and on all trials conducted by the manufacturer, Servier.77 
Trial participants were diagnosed with major depressive disorder according to DSM-IV criteria. All 
but two studies used the Hamilton scale for assessing severity of depression. At baseline, patients 
had a mean Hamilton score of 27.78 The main outcome was change in mean depression score at the 
end of the trial. Response and remission, as defined by the original trials, were studied as secondary 
outcomes. The majority of the studies defined response as a 50% reduction in depression score and 
remission as a Hamilton score of 7 or less or a MADRS score of 12 or less. 
Agomelatine was superior to placebo for the primary outcome, with a standardized mean 
difference of 0.24. Agomelatine was also superior to placebo for response: the relative risk was 
1.25. No statistically significant difference between agomelatine and placebo was found for 
remission.79 Patients on agomelatine were no more likely than patients on placebo to discontinue 
treatment due to adverse events or due to any reason.80 There were no statistically significant 
differences between agomelatine and other antidepressants (considered as a group) for the primary 
or secondary outcomes.81 There was evidence of publication bias in the literature: agomelatine was 
not superior to placebo for response or remission in the unpublished studies. Published studies 
tended to favour agomelatine versus other antidepressants, whereas unpublished studies tended to 
favour established antidepressants over agomelatine.82 
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The authors conclude that agomelatine is an effective antidepressant, but that its effect size 
when compared to placebo is small. Agomelatine did not show superiority over placebo for 
remission; the authors note that this could be because some of the trials did not report this 
outcome.83 The authors make an indirect reference to the antidepressant debate by noting that 
agomelatine’s effect size might cast doubt on its clinical relevance and lend credence to the critics’ 
argument that the use of antidepressants should be limited.84 They suggest that such a conclusion 
should be considered with three caveats. They note that placebo treatment has a significant effect 
size in depression,85 presumably suggesting that this leads to smaller effect sizes for active drugs. 
They point out that effect sizes for active drugs are greater in relapse prevention studies. 
Furthermore, they argue that the small effect sizes for antidepressants are similar to effect sizes for 
drugs used in other fields of medicine, such as ACE inhibitors for prevention of cardiovascular 
events and thrombolysis for survival in acute stroke.86 This discussion is germane to the question of 
clinical relevance: how great should the difference favoring active drugs be to justify their use in 
clinical practice? I touch on these questions in the Conclusion. The guidelines do not comment on 
the magnitude of agomelatine’s effect size or its clinical relevance; they merely point out 
agomelatine’s statistical superiority over placebo.87 
 Pae et al. 2015 is a meta-analysis of short-term trials of vortioxetine for major depressive 
disorder. Vortioxetine is the newest SSRI; it received FDA approval in 2013. Twelve randomized 
controlled trials comparing vortioxetine to placebo or to another antidepressant (venlafaxine, 
duloxetine, or agomelatine) were included. Mean Hamilton or MADRS scores at baseline ranged 
from 28.5 to 34.1.88 
 The primary outcome was change in depression score on the 24-item Hamilton scale or the 
MADRS scale. Secondary outcomes were response and remission. Response was defined as a 50% 
or greater reduction in initial HAMD/MADRS score and remission as 7 points or less on the 
HAMD or 10 points or less on the MADRS. 89 
 Intention-to-treat data was available for 4947 patients. Vortioxetine was superior to placebo, 
with a standardized mean difference of -0.217. Vortioxetine was superior to placebo for response 
and remission: odds ratios were 1.652 and 1.399, respectively. There was significant heterogeneity 
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among trials, but no single trial was found to have a strong effect on the overall results.90 For 
discontinuation for any reason, there was no statistically significant difference between vortioxetine 
and placebo, but the discontinuation rate due to adverse events was significantly higher in the 
vortioxetine than the placebo group. The discontinuation rate due to lack of efficacy was 
significantly higher in the placebo group. 91 
Intention-to-treat data was available for 2843 participants for vortioxetine versus other 
antidepressants (grouped together).92 There was no statistically significant difference for 
vortioxetine versus the other drugs for the primary outcome93 or for response or remission.94 
The authors note that even though the statistical superiority of vortioxetine over placebo was 
demonstrated, the standardized mean difference of -0.22 is of questionable clinical relevance. They 
point out that the SMD translates to a two-point difference in MADRS score.95 The authors refer to 
the debate on the minimal clinically important difference (MCID) in drug-placebo comparisons.96 
Using Duru and Fantino’s criteria for the MCID – a difference of 2 points on the MADRS or a 10% 
difference in response rate – Pae and colleagues argue that “vortioxetine may meet the marginal 
standard criterion for an antidepressant to be considered effective for treating MDD.”97 This is 
directly pertinent to the issue of clinical relevance, which I touch on in the Conclusion. The 
guidelines offer no comment on the magnitude of vortioxetine’s effect size compared to placebo or 
on its clinical relevance. 
 Jakubovski et al. 2016 is a meta-analysis studying the relationship between SSRI dose and 
treatment response.98 It is not primarily a study of SSRI efficacy versus placebo, but it is discussed 
here because the guidelines include it amongst the meta-analyses they muster in support of the 
overall argument that antidepressants are effective treatments for depression and because it is highly 
relevant to the critics’ “active placebo” argument discussed later. 
 Forty studies with forty-nine active treatment arms with 10 039 patients were included. The 
drugs studied were fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram and escitalopram. 
SSRI doses were converted to imipramine equivalents.99 Jakubovski et al. found a statistically 
significant association between SSRI dose and efficacy in reducing the severity of depression, as 
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measured on the Hamilton or Montgomery-Åsberg scales.100 The result was statistically significant 
both when SSRI dose was examined by dosing category and when it was examined as a continuous 
variable.101 The result remained significant when only trials using intention-to-treat data were 
included.102 There was also a statistically significant association of SSRI dose with treatment 
response. This finding remained significant when only intention-to-treat data was included.103 
The meta-analysis also investigated the relationship between dose and adverse events. There 
was a statistically significant association between increased SSRI dose and dropout because of 
unwanted effects.104 However, there was a small statistically significant association between higher 
SSRI dose and a lower likelihood of dropout for any reason.105 
The authors conclude that the “meta-analysis demonstrated a significant association between 
higher SSRI doses and greater measured efficacy of SSRIs […]”106 and that this benefit comes at 
the cost of increased adverse events.107 The guidelines echo this conclusion.108 This is one way of 
interpreting the results. However, the results might also be compatible with the Kirsch-Moncrieff 
argument that antidepressant superiority over placebo is due to unblinding because of side effects.  
To summarize: the guidelines assert that antidepressants are clearly superior to placebo in 
acute-phase treatment of depression, and that no methodologically valid meta-analysis questions 
their effectiveness. It is difficult to agree with this claim on the basis of the above review. No 
specific criteria are presented in the guidelines for assessing the methodological validity of meta-
analyses. The guidelines do note that they try to focus on studies in which the effects of publication 
bias is minimal, and which are otherwise as independent as possible of the pharmaceutical 
industry.109  
However, Kirsch et al. 2008 is described as a good quality study, well suited to application 
in the Finnish context. This study is cited in support of the claim that antidepressants are effective 
in treating all severities of depression. As we have seen, the study itself reaches quite a different 
conclusion: that antidepressants are effective only for the most severely depressed patients, and that 
even for those patients, their apparent superiority over placebo derives mostly from the declining 
efficacy of placebo. It seems reasonable to conclude that at least this study is a methodologically 
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valid meta-analysis that puts into question the effectiveness of antidepressants, and thus contradicts 
the claim that no such meta-analysis exists.  
It should also be noted that studies such as Mellander et al. 2008 and Gibbons et al. 2012 
explicitly refer to the conclusions drawn by Kirsch and colleagues, and attempt to show that a 
different analysis of the data yields a different conclusion. If Kirsch et al. 2008 reached the 
conclusion that antidepressants are generally effective, as the guidelines imply, it would make no 
sense for these other studies to position themselves in relation to it, as there would be no need to 
defend the mainstream view of antidepressants against the study’s conclusions. 
 
1.2 Long-term treatment 
The guidelines maintain that antidepressants are not only superior to placebo for acute treatment of 
depression, but that they are effective for the prevention of relapse. The guidelines argue that 
maintenance treatment is generally well tolerated, because patients have already demonstrated 
response to antidepressants. They note that it is common for patients to discontinue treatment, but 
claim that this is rarely due to unwanted drug effects.110 The guidelines base these arguments on 
four meta-analyses. 
 The first, Geddes et al. 2003 studied 31 discontinuation trials.111 All the 4410 patients 
included had responded to active drug treatment in the acute phase of depression. Patients were 
randomly allocated to continue or discontinue active drug treatment and were followed up for at 
least one month.112 Two trials were on noradrenaline reuptake inhibitors, four on MAO inhibitors, 
15 on TCAs, 10 on SSRIs, and one on some other type of antidepressant. The trials were published 
between 1973-2001. There were various criteria used for relapse, ranging from specific scores on 
the Hamilton or the Montgomery-Åsberg scale to hospital admission or the indication to change 
drug treatment.113  
 Treatment with the active drug consistently reduced the risk of relapse. The average relapse 
rate in the placebo groups was 41%; in the drug groups, it was 19%. The pooled odds ratio for 
relapse was 0.30. In the drug groups, more patients (18%) withdrew from the trials than in the 
placebo groups (15%).114 Even though the studies were quite heterogeneous in terms of the drugs 
studied, duration of the maintenance treatment, and the definition of relapse, the results consistently 
favored the effectiveness of active drug treatment in the prevention of relapse.115 
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 It should be noted that almost half (15) of the 31 studies were of TCAs, which are not the 
first line of drug treatment for depression today. A more fundamental problem with the trials was 
that all patients had been on active drug treatment prior to the trials. The authors note that this raises 
the possibility that some of the relapses in the placebo groups were due to withdrawal of the active 
drug rather than to an actual recurrence of depression. The authors point out that, if this is the case, 
the effectiveness of maintenance treatment with antidepressants might have been inflated.116 The 
guidelines ignore this potential weakness.  
 The second study, Hansen et al. 2008, is a review and meta-analysis of comparative and 
placebo controlled trials of newer antidepressants for the prevention of relapse and recurrence of 
depression. 117 Four trials comparing antidepressants head-to-head and 23 trials comparing 
antidepressant with placebo were included.118 The antidepressants studied were all “second-
generation”, i.e. representative of current clinical practice. Included were bupropion, citalopram, 
duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, 
trazodone, and venlafaxine. The study investigated two questions: are there differences in the 
effectiveness of antidepressants in maintaining remission for adults with major depressive disorder? 
What is the overall effect size for drug versus placebo, and does it persist over time?119 
 All patients had responded to acute treatment with an antidepressant prior to randomization 
to continue active or placebo treatment. The definition of this response varied. Some trials used a 
specific cut-off point on the Hamilton scale, the Beck Depression Inventory (BDI), the MADRS 
scale, or the CGI scale (such as <10 points on the Hamilton scale); some a reduction of initial 
depression score by a specific percentage (such as a 50% reduction in Hamilton score); and some 
studies combined these ratings with DSM diagnostic criteria.120 The authors note that in most trials, 
loss of response or remission was defined by an increase in Hamilton or MADRS score above a 
specific cut-off point.121 However, no exact definition for relapse or remission is given for any of 
the trials, even though the exact criteria for inclusion are given for all of them. 
 The authors did not consider individual drugs versus placebo, but combined the different 
drug treatment groups into one, which was compared to the placebo group. The placebo-controlled 
trials showed superiority of active drug over placebo in relapse prevention. In the twelve trials with 
a follow-up period of less than one year, 22% of patients in the active drug group relapsed, whereas 
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42% of patients in the placebo group did so. In the 11 trials that were longer than 12 months, the 
relapse rate in the active treatment group was 26% and in the placebo group it was 48%. The meta-
analysis of trials shorter than 12 months yielded a pooled relative risk for relapse of 0.54, 
translating into a number-needed-to-treat of 5 to prevent one additional relapse. In the longer trials, 
the overall relative risk of relapse was 0.56, and the NNT was 5.122 There were four trials comparing 
different active drugs head-to-head; were no significant differences between them.123 
Twenty-two trials provided sufficient data for analyzing adverse events; loss to follow-up in 
these trials was 7% in the active treatment group and 5% in the placebo group. Based on data from 
18 trials, there was no statistically significant difference in loss to follow-up due to adverse events 
between active and placebo treatment. Overall, 50% of patients assigned to active treatment, and 
68% of patients assigned to placebo were lost to follow-up.124  
 The study shows clear superiority of active drugs over placebo, and the guidelines note the 
relative risk of 0.56.125 However, the guidelines describe this as the relative risk in intention-to-treat 
analysis.126 Hansen et al. 2008 mentions that intention-to-treat data was included for trials for which 
it was available.127 However, their paper does not indicate how many trials included intention-to-
treat data. The authors did assess the quality of each trial according to several criteria, one of which 
was the inclusion of intention-to-treat analysis.128 Only two of the placebo-controlled trials were 
rated as good quality, the rest were categorized as fair quality.129 It is impossible to tell which of 
these trials included intention-to-treat analysis on the basis of the article.  
Intention-to-treat is crucial here, since so many patients in the trials were lost to follow-up. 
It would therefore be essential to know how the trials categorized patients that dropped out. Given 
that 50% of patients in the drug group and 68% in the placebo group were lost to follow-up, it is 
hard to draw any conclusions from the study’s results. The guidelines ignore this. 
 The third study, Williams et al. 2009, is a meta-analysis of eleven antidepressant 
maintenance trials published between 1998-2007.130 The study compared relapse rates among 
patients receiving active drug and placebo in long-term maintenance treatment. In nine of the trials, 
maintenance treatment was preceded first by 0-12 (mean = 7.5) weeks of acute treatment and 
second by 0-26 (mean = 17) weeks of continuation treatment with a specific antidepressant. Only 
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patients who had been categorized as remitters or responders in the acute phase moved onto the 
continuation phase, and again, only those who were remitters/responders in continuation treatment 
were randomized into double-blind placebo controlled long-term (24-156 weeks, mean = 60) 
maintenance treatment.131 The baseline Hamilton score for admission to the acute phase ranged 
from 14 to 18.132 For both the acute and continuation phases, remission was defined as a Hamilton 
score of eight or lower and response as a score of twelve or less plus a 50% reduction from the 
baseline score.133 
 In one trial, 10 sessions of electroconvulsive therapy (ECT) were used for acute treatment. 
Another trial included patients who did not meet DSM depression criteria at baseline and who then 
received two months of placebo treatment before being randomized to maintenance treatment with 
placebo or sertraline. 134 In almost all the trials, the active drug was an SSRI or SNRI in widespread 
clinical use today; the drugs were fluoxetine, citalopram, sertraline, venlafaxine, escitalopram, and 
duloxetine. One trial used a TCA, nortriptyline, and another used a nortriptyline-lithium 
combination.135 The study that used nortriptyline-lithium was the only one that included psychotic 
patients.136  
 The risk of relapse was 23% for drug and 51% for placebo at one year, 34% for drug and 
62% for placebo at two years, and 45% for drug and 7% for placebo at three years.137 In all the 
individual studies, relapse rates were higher for placebo than for active drug.138 The number of 
previous episodes or the baseline Hamilton score in the acute phase did not affect relapse rates.139 
The final meta-analysis, Glue et al. 2010, studied 54 double-blind placebo-controlled 
relapse prevention trials.140 SNRIs were studied in 21 of the trials and SSRIs in another 21 trials. 
Two trials studied noradrenaline reuptake inhibitors, five MAOIs, and eight trials investigated other 
types of antidepressants (gepirone, mianserine, bupropion).141 In a majority of studies, patients were 
diagnosed with major depressive disorder. In nine studies, other depressive diagnoses such as 
bipolar disorder and dysthymia were included. 31 studies used various DSM criteria; the rest used a 
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variety of other diagnostic criteria, such as Research Diagnostic criteria. Various criteria for 
defining response and relapse were used.142   
 Odds ratios for relapse were determined based on drug class, patient age, diagnostic system 
and depression subtype, treatment duration, and year of publication. All classes of active drug were 
found to reduce the risk of relapse. The result was statistically significant. There was statistically 
significant heterogeneity between drug classes; the exclusion of MAOI trials eliminated the 
statistical significance of this heterogeneity.143  
 The authors note that for patients who experienced response to active medication in the 
acute phase of treatment, the odds of relapse were reduced by two thirds by continued 
antidepressant use.144 The authors point out the same alternative explanation for such results that 
Moncrieff and Kirsch do, i.e. that higher relapse rates in the placebo group might be due to drug 
withdrawal rather than a true relapse of depression. They argue that were this the case, active drugs 
would fare better in trials where patients randomized to placebo were abruptly moved from active 
drug to placebo than in those trials where the active drug patients were taking in the acute phase 
was gradually down-titrated before they started receiving only placebo. Data on drug titration was 
available in 28 studies, and in these, patients were abruptly switched from drug to placebo in two 
trials, whereas in the other trials active drug was down-titrated for a period of 1-16 weeks. The 
authors found no “obvious increase in patients relapsing early in the post-randomization phase” 
when comparing abrupt and gradual withdrawal.145  
 The authors also point out the possibility of publication bias, but maintain that “diligent 
searches were made of pharmaceutical company and non-commercial clinical trial databases” in 
order to discover all relevant trials.146 The authors do not indicate what kind of access they had to 
pharmaceutical company databases, and they did not obtain full data from the FDA, so some 
publication bias may remain. 
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2: Placebo: the Kirsch-Moncrieff argument 
In this section I summarize the argument presented by Kirsch and Moncrieff that antidepressants 
are not significantly superior to placebo. Their arguments move from the observation of the 
moderate effectiveness of antidepressants to attempting to explain this relative lack of efficacy; this 
further elucidation of the argument is presented in section 3. A critical examination of the validity 
of these arguments is given in section 4. 
 
2.1 Moncrieff on antidepressants versus placebo 
Moncrieff presents the bulk of her version of the placebo argument in chapter nine of The Myth of 
the Chemical Cure, in which she asks whether such a thing as an antidepressant exists. She notes 
that textbooks state the superiority of antidepressants over placebo to be around 20-40%.147 She 
points out that most antidepressant trials show slight superiority for drug over placebo, but that 
some trials show placebo to be equal or even superior to drug.148 As is typical of Moncrieff, she 
relies heavily on early antidepressant trials.  
 There are four elements of the drug/placebo difference that Moncrieff discusses: drug versus 
placebo for short-term treatment, the effect of the severity of depression on drug/placebo 
differences, drug versus placebo for long-term treatment, and drug versus placebo for the long-term 
outcome of depression. I discuss each of these lines of argument below. In the chapter of The Myth 
of the Chemical Cure in which she presents the bulk of her argument on these issues, she also 
discusses the question of the efficacy of other active drugs not considered antidepressants for the 
treatment of depression, but I will consider this discussion in the section on the “active placebo” 
argument. 
 
2.1.1 Short-term treatment 
Moncrieff refers to a review of trials of imipramine versus placebo published in 1975, in which a 
majority of trials was found to show no superiority of this older tricyclic antidepressant over 
placebo.149 She points to both older and more recent reviews of trials which suggest the 
effectiveness of antidepressants, tricyclics in particular, is not impressive. She discusses the 
Medical Research Council trial of imipramine, phenelzine, electroconvulsive therapy and placebo 
conducted in the UK. This early study, published in 1965, showed little difference between 
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phenelzine, an MAO inhibitor, when compared to placebo. Likewise, the tricyclic antidepressant 
imipramine did not fare much better than placebo.150  
Another study she refers to, published by the National Institutes of Mental Health in 1970, 
compared imipramine, chlorpromazine and placebo. Chlorpromazine is an early dopamine 
antagonist, and is used as an antipsychotic medication, but is not indicated for depression. 
Moncrieff notes several weaknesses in how the data in this study is presented, and that the results 
were “essentially negative”.151  
Moncrieff maintains that newer meta-analyses show lower superiority for drug over 
placebo.152 Her choice of studies here is curious. Storosum et al. 2001, the newest study she refers 
to, evaluates the effectiveness of TCAs versus placebo, even though it was published in the SSRI 
era.153 Bech et al. 2000, the second one she refers to here, is a meta-analysis of a single drug, 
fluoxetine.154 The results favor fluoxetine. The third study Moncrieff refers to here, Khan, Warner 
& Brown 2000, is a meta-analysis examining suicide risk and symptom reduction in the active 
treatment and placebo arms of antidepressant trials.155 It concludes that receiving placebo in an 
antidepressant clinical trial poses no additional suicide risk for the depressed patient. The authors 
also note that patients receiving placebo experience significant symptom reduction, but not to the 
same degree as those receiving the active drug.156  
Moncrieff then argues that categorical figures are misleading and that Kirsch’s 2002 paper 
demonstrates this.157 Kirsch et al. 2002 used the Freedom of Information Act to request trial data 
submitted to the FDA for six SSRIs: fluoxetine, paroxetine, sertraline, venlafaxine, nefazodone, and 
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citalopram. All the trials used the Hamilton depression scale to evaluate patients. 38 trials for which 
last observation carried forward data was available were included in the meta-analysis.  
Moncrieff points out that though the analysis shows an 18 % superiority for drug over 
placebo in categorical terms, this only means a 1.7 point difference on the Hamilton scale.158 She 
goes on to assert that this difference is “too small to be meaningful” by “all assessments of clinical 
validity”.159 Moncrieff notes that the difference is so small that it could easily be explained by non-
specific drug effects or “enhanced placebo effects”.160 
The next study that Moncrieff draws on in support of her argument is the systematic review 
of antidepressant research conducted by NICE in the UK.161 Moncrieff notes that the review did 
find a statistically significant difference between drug and placebo, but concluded that this 
difference was so small that its clinical relevance was questionable. However, instead of reaching 
the conclusion that drug/placebo differences are clinically irrelevant, Moncrieff points out that 
NICE instead analyzed the data in terms of differences in response and remission rates, which 
enabled them to conclude that drug/placebo differences are clinically significant, even though the 
same data had led them to question that significance.162  
Unfortunately, I was unable to obtain a copy of the full 2004 NICE guideline, despite 
repeated online searches and ordering a copy from the British Library. The version I was able to 
obtain from the British Library only included the guidance, not the review of the evidence on which 
the guidance is based. It is not possible to properly explore the critics’ arguments relating to NICE’s 
materials. 
 
2.1.2 Severity 
Moncrieff moves onto considering the question of whether the efficacy of antidepressants is 
dependent on the severity of depression. This is an important question, since antidepressants might 
be ineffective for milder forms of depression, but have a more significant effect in more severe 
forms of the disorder. This notion is echoed in the guidelines, which state that treatment with 
antidepressants is especially important in severe depression.163  
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NICE has gone as far as recommending against the use of antidepressants for mild 
depression, and recommending them only for moderate and severe depression.164 The 2004 NICE 
guideline states: “Randomised controlled trial (RCT) evidence indicates that for many patients there 
is little clinically important difference between antidepressants and placebo, and the placebo 
response is greatest in mild depression.”165 In the case of moderate or severe depression, NICE is 
more careful in its assessment than the Finnish guidelines, stating that “[…]There is more evidence 
for the effectiveness of antidepressant medication than in milder depression.”166 Noting that 
medication is as effective as psychological interventions, and is cheaper, NICE recommends that 
the clinician offer antidepressants to moderately depressed patients.167 
Moncrieff argues against the notion that antidepressants are effective in more severe 
depression. Again, she refers to some older studies to support her argument. First, a 1976 review 
found that supposed predictors of antidepressant response were not based on much evidence.168 That 
study concluded that the relationship of depression severity and antidepressant response is 
unclear.169 The second study, a bit more recent, that she refers to found that the evidence on whether 
so-called endogenous depression - which is quite severe - responds better or worse to 
antidepressants than other types of depression was mixed.170  
She moves on to discuss meta-analyses published in the 1990s and 2000s. She notes that 
Angst et al. 1993 found antidepressants to show greater superiority over placebo for patients with 
more severe depression, but argues that these effects were not strong, and that they did not reach 
statistical significance for the most part.171  
Angst et al. 1993 is a meta-analysis of 38 trials of moclobemide versus placebo or 
tricyclics.172 The authors present subscales of the Hamilton scale: psychic, somatic, retardation, and 
agitation.173 They investigated drug versus placebo response on these subscales and the effect of 
baseline severity of depression on response. Response was defined as a reduction in Hamilton score 
of 50% or more.174 A score of less than 23 was defined as low, 23-27 as medium and 28 or greater 
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as high on the total Hamilton scale. In the placebo group, statistical significance was reached only 
on the retardation subscale, with 34% of patients with a low initial HAMD score and 16% with a 
high score achieved response.175 For moclobemide, more severely depressed patients tended to 
respond better, with the results statistically significant on the somatic and agitation subscales.176 
More severely depressed patients also tended to respond better to the TCAs imipramine and 
clomipramine, with statistically significant results on the psychic, somatic, retardation, and agitation 
subscales for the former, and only on the agitation subscale for the latter.177 
More pronounced effects of severity on antidepressant versus placebo differences were 
found in Khan et al. 2002, but Moncrieff points out that full data was provided only for 
“investigational” antidepressants.178 Khan et al. 2002 examined 45 trials conducted for the approval 
of the following antidepressants: fluoxetine, sertraline, paroxetine, venlafaxine, nefazodone, 
mirtazapine, and bupropion. The trial data was extracted from the FDA database. Trial outcomes 
were categorized into superior, supportive, and equivocal based on drug versus placebo response.179 
A superior outcome here means that the active drug was clearly statistically superior over placebo, 
equivocal that there was no difference, and supportive something in between.180 The trials were 
divided into three groups based on mean initial severity of depression, assessed on the Hamilton 
scale. In the least severe group, the mean Hamilton score was 24 or less, in the next group, between 
24 and 28, and in the most severe group, 28 or more.181 
48% of trials were found to show superiority of the investigational antidepressant over 
placebo, and 64% of trials showed superiority of an established antidepressant over placebo. For the 
group of trials with the lowest initial mean Hamilton score, only one in ten trials showed statistical 
superiority over placebo for the investigational antidepressant. In the second group, such superiority 
was found in 49% of trials, and in the group of trials with the highest mean Hamilton score, this 
figure was 71.4%.182 
There was a statistically significant relationship between the mean initial Hamilton score 
and change in the score in the investigational antidepressant arms of these trials. No such 
statistically significant relationships were found for established antidepressants or placebo.183 The 
authors summarize their findings by noting that “the higher the mean initial HAM-D score, the 
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greater the change with antidepressants […].”184 The mean change in Hamilton score in the 
investigational antidepressant arms of the trials was 9.8 in the group of trials with the lowest initial 
severity, 10.5 in the middle severity group, and 12.6 in the group with the highest severity.  
 Moncrieff then discusses an unpublished version of the 2008 Kirsch et al. 2008 meta-
analysis discussed above. She points to the results I have already discussed: that patients on the 
active drug responded more to the treatment as the initial severity of depression rose, whereas the 
response to placebo diminished. She emphasizes that the drug/placebo difference was only four 
points for the most severely depressed patients – a difference she considers “of doubtful clinical 
relevance”.185 She goes on to argue that the difference is so small that it could be explained by 
“active placebo effects”. She also suggests that the response pattern in the group of patients 
receiving active drug could be explained by regression to the mean, i.e. by the patients who are 
initially the most depressed tending to improve the most.186  
 Moncrieff notes that two other relatively recent meta-analyses – Walsh et al. 2002 and 
NICE 2004 – showed no consistent relationship of the initial severity of depression with drug 
response.  
Walsh et al. 2002 investigated how placebo response in antidepressant trials has changed 
over the years.187 Much like Khan, Warner & Brown 2000, the authors situate their study in the 
context of the debate on whether it is ethical to include a placebo group in antidepressant trials, 
given that supposedly effective medication is available.188 The study included seventy-five 
antidepressant trials conducted between 1981-2000. Both SSRI and TCA trials were included.189 As 
usual, response was defined as a 50% reduction in Hamilton score.190 The study’s main objective 
was to ascertain whether placebo and drug response correlates with year of publication, i.e. whether 
these responses have changed over the years.191 
Walsh et al. 2002 found that the proportion of patients responding to placebo increased 
significantly with year of publication.192 The same was true for patients responding to active drug, 
though the latter result was not statistically significant, if certain covariates were included.193 The 
authors note that “[t]here were no statistically significant associations between the proportion of 
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patients taking placebo who responded and pro-rated average initial HRSD score.”194 In the analysis 
of the active drug groups, average initial Hamilton scores were only analyzed as a covariate of TCA 
response. The relationship of this covariate with drug response was found to be statistically 
insignificant. 
 Moncrieff then discusses a number of individual trials which show a stronger antidepressant 
effect in more severe depression, but which do so on the basis of post hoc analysis, i.e. by looking 
for statistically significant effects in the data without predetermining which outcomes will be 
considered. This mode of inquiry can easily yield positive results because of random effects.195  
 Moncrieff then points out that it “has long been believed that antidepressants are relatively 
ineffective in severe depression accompanied by psychotic delusions.”196 Arguing that it is not the 
presence of psychotic symptoms but rather the general ineffectiveness of antidepressants that 
explains the apparent lack of significant antidepressant effects in psychotic depression, she refers to 
a study, which found that the severity of depression rather than the presence of delusions predicted 
a more modest response to antidepressants.197 This study, Kocsis et al. 1990, investigated response 
to imipramine and amitriptyline, both TCAs, in different severities of depression and in non-
psychotic versus psychotic depression.198  
The study situates itself in the context of discussion on the optimal treatment in psychotic 
depression: on whether the modest response to TCAs often observed in psychotically depressed 
patients is caused by the psychosis or by the severity of their depression.199 The study included 132 
depressed patients, who were categorized into non-psychotic severely depressed, non-psychotic 
moderately depressed and psychotically depressed. Patients who fulfilled criteria for schizoaffective 
disorder were excluded, but it should be noted that patients with both unipolar depression and 
bipolar illness were included in both the non-psychotic and psychotic groups. Severity of 
depression was rated on the Hamilton scale both before and after the four-week treatment period, 
and patients were divided into severely and moderately depressed by using the median initial 
Hamilton score in the nonpsychotic group as the cut-off point. Patients were categorized as good, 
intermediate or poor responders based on an algorithm combining Hamilton, SADS-C global 
assessment scale, clinical global improvement, and clinical global severity ratings.200 
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67% of moderately depressed patients were found to be good responders, whilst 39% and 
32% of the severely and psychotically depressed, respectively, were categorized as good 
responders. Difference in response among the three groups was statistically significant. Difference 
in response was not statistically significant when comparing the severe and psychotic groups, but 
was significant when comparing the moderately depressed group with the combined severe and 
psychotic groups.201 The authors conclude that the results suggest that severely depressed patients 
might respond less favorably to antidepressant treatment than moderately depressed ones.202  
Moncrieff argues that another study of bipolar illness strengthens her case. This study, Sachs 
et al. 2007, found that patients in the depressive phase of bipolar disorder, who were taking mood 
stabilizer drugs, did not respond better to drug than to placebo.203 The study was a randomized, 
double blind trial comparing the use of paroxetine or bupropion with placebo as adjunct therapy for 
depression in type I and II bipolar disorder. It included 366 patients who were randomized to active 
or placebo treatment for 26 weeks. The primary outcome was euthymia for eight weeks.204 All of 
the patients were taking mood stabilizer drugs: lithium, valproate, carbamazepine or other drugs 
approved by the FDA for preventing mania.205  
Supplementing mood stabilizer treatment with paroxetine of bupropion was not superior to 
supplementation with placebo. 27.3% of patients in the placebo group experienced euthymia for 
eight weeks, whereas 23.5% of patients in the active drug groups did so. This result was not 
statistically significant (p=0.40).206 Noting that depressions in bipolar illness tend to be more severe 
than other types of depression, Moncrieff argues that this study provides further support for her 
claim that antidepressants are no better than placebo even in the most severe forms of depression.207  
 
2.1.3 Long-term treatment 
Moncrieff notes that continuation of antidepressant treatment for several months after an acute 
episode has resolved is conventionally recommended.208 She argues that even though several studies 
have shown that patients are at greater risk of relapse if they stop taking antidepressants, the 
discontinuation design of these studies undermines their results. She refers to several studies which 
demonstrate that antidepressant discontinuation results in adverse events.209  
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Dilsaver et al. 1987 reviews withdrawal symptoms of patients whose TCA treatment has 
been discontinued.210 The authors outline four different types of withdrawal “syndrome”: 
gastrointestinal and general somatic distress possibly accompanied by anxiety, sleep disruption, 
movement disorders, and hypomania and mania.211  They note that it is possible to erroneously 
interpret withdrawal symptoms as relapse.212 Hindmarch et al. 2000 investigated the effect of 
discontinuation of fluoxetine, sertraline, paroxetine and citalopram on cognitive and psychomotor 
performance, social functioning, and depressive symptoms.213 Significant effects were not found for 
the discontinuation of fluoxetine, sertraline, or citalopram – the discontinuation of paroxetine did 
produce such effects on the measures adopted.214 The authors note that depressive symptoms 
reappeared so rapidly in patients discontinuing paroxetine that it is more likely that they were 
experiencing antidepressant discontinuation syndrome rather than recurrence of depression.215 They 
also point out that such a withdrawal syndrome should not be considered common to all SSRIs, 
since it was notable only for paroxetine.216 
 Moncrieff argues that withdrawal symptoms are not distinguished from true relapse in 
discontinuation studies, which means that some of the relapses observed in placebo groups might be 
due to discontinuation symptoms. She also speculates that such symptoms could unblind patients, 
i.e. they realize they have been withdrawn to placebo. Given that generally only patients who have 
already responded to drug treatment are included in continuation/maintenance studies, she argues 
that such unblinding may cause patients to think they will do worse on placebo, causing them to 
have a worse outcome.217 
 Moncrieff includes only one review of discontinuation studies as evidence for her argument 
in this section. Viguera et al. 1998 examined 27 trials with 3037 patients.218 In each trial, one group 
of patients continued on antidepressant treatment and another discontinued it. In 25 trials, those 
discontinuing treatment were withdrawn to placebo. In 17 trials, the active drug was a TCA, in five, 
it was a MAOI, and in another five, it was an SSRI.219 The primary outcome was relapse, defined 
variously by clinical assessment, some psychiatric rating scale, Research Diagnostic Criteria or 
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hospital readmission.220 Patients had been stabilized for an average of 23.1 weeks (range 0-192) 
before discontinuation, and were followed up for an average of 16.6 months (range 6-60). 
 Relapse rates for patients withdrawn from antidepressant treatment were 6.24 per cent per 
month (SD ±5.34) and 1.85 per cent per month (SD ±1.51) for patients continuing active drug 
treatment.221 There was a 3.37-fold difference in the time to 50% risk of relapse favoring active 
drug treatment.222 The ratio of relapse rates in the placebo versus the drug group fell over time. The 
ratio of placebo versus drug relapse rates was 3.69 at two months, 2.21 at 12 months, and 1.34 at 
five years.223 Relapse rate was not associated with length of stabilization on antidepressant.224 In 
fact, as Moncrieff notes, relapse rates were higher for those who had been stabilized on an 
antidepressant for longer, but these results were not statistically significant.225 There were no 
significant differences in relapse rates between those studies that used an abrupt discontinuation of 
active drug treatment and those that used gradual withdrawal. In fact, the relapse rates were higher 
in the studies that used gradual withdrawal, but the result was not statistically significant.226 
 The authors argue that there are two possible ways of interpreting their results. The first is 
the conventional one: that the clear superiority of long-term antidepressant treatment over 
withdrawal implies that such drugs have an important prophylactic effect in recurrent depression. 
The second is that “[…] drug discontinuation itself may represent a clinically significant stressor 
that may temporarily increase relapse risk.”227 The authors point out that this hypothesis is 
consistent with the finding that relapse risk off versus on drug treatment decreased over time.228 
 Moncrieff argues that “People who believe that their recovery is attributable to 
antidepressant drugs are likely to feel anxious and vulnerable if those drugs are withdrawn.”229 She 
maintains that psychological effects are probably as significant, if not more so, than the 
pharmacological stress hypothesized in Viguera et al. 1998. Moncrieff further asserts that 
“psychological explanations would fit with the longer time to relapse and might explain how people 
who have been stable for longer periods are more at risk, since they are likely to be more 
psychologically dependent on the drugs.”230  
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2.2 The placebo argument: Kirsch 
Kirsch’s version of the placebo argument in The Emperor’s New Drugs relies heavily on meta-
analyses he has co-authored. The most recent one, Kirsch et al. 2008, has already been discussed in 
section 2.1; I will discuss only the two other studies here. 
The first one is the 1998 study by Kirsch and Sapirstein.231 The aim of this meta-analysis 
was to study response to placebo in antidepressant trials.232 Kirsch & Sapirstein distinguish placebo 
“response” from the “placebo effect.” They define the placebo response as the “change that occurs 
following administration of a placebo.”233 They note that this response could also come about 
without the administration of a placebo – it could occur because of spontaneous remission, a change 
in the patient’s life circumstances, or other such factors not related to the patient taking the placebo 
pill. The authors define the placebo effect as “the difference between the placebo response and 
changes that occur without the administration of a placebo.”234 In other words, the “placebo effect” 
is the effect that the administration of a placebo has, when other causes for a patient’s improvement 
have been eliminated. 
The meta-analysis investigated two questions: How big is the placebo response compared to 
the response to active drug in antidepressant trials? How big is the “placebo effect” in such trials? 
The first question was answered based on a meta-analysis of randomized controlled drug trials.235 
The second question was answered on the basis of comparing placebo response in such trials with 
the response of people assigned to the waiting-list group in psychotherapy trials. The authors note 
that in drug trials, a no-treatment group is usually not included, but in psychotherapy trials, there is 
often a group of patients randomized to remain on the waiting list.236 In other words, in 
psychotherapy trials there is a group of patients who do not receive any treatment. In order to tease 
out the placebo “effect” it is necessary to compare patients receiving placebo with patients 
receiving no treatment. 
Randomized placebo-controlled trials of patients between the ages of 18-75 with a primary 
diagnosis of depression in the acute phase of treatment that included sufficient data to calculate 
effect sizes were included in the first part of this meta-analysis.237 19 trials with a total of 2 318 
patients were considered to meet the criteria. The range of medications studied was considerable: 
amitriptyline, amylobarbitone, fluoxetine, imipramine, paroxetine, isocarboxazid, trazodone, 
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lithium, liothyronine, adinazolam, amoxapine, phenelzine, venlafaxine, maprotiline, 
tranylcypromine, and bupropion. 238 Only fluoxetine and paroxetine are SSRIs.   
Mean effect sizes were 1.55 SDs for medication response and 1.16 for placebo response, 
giving a mean effect for medication of 0.39 SDs. Kirsch & Sapirstein note that 75% of the response 
to medication is accounted for by placebo response, leaving 25% of the drug response as the “true” 
drug effect.239 In other words, they write, “[…] for a typical patient, 75% of the benefit obtained 
from the active drug would also have obtained from an inactive placebo.”240 
The authors considered the possibility that the type of medication used might have an 
impact on drug and placebo response rates.241 They categorized the medications into 
TCAs/tetracyclics, SSRIs, other antidepressants, and other medications. The last category includes 
amylobarbitone, lithium, liothyronine, and adinazolam, which were studied in the drug trials, but 
which are not conventionally considered antidepressants.242 The placebo response as a proportion of 
active drug response was 0.74 for SSRIs and 0.76 for the other categories.243 Kirsch notes that the 
type of active medication used had virtually no effect on the superiority of drug over placebo.244 
For the second part of the meta-analysis, 19 psychotherapy trials with no-treatment or 
waiting list groups were included.245 There were no statistically significant differences in the 
severity of depression between the drug and psychotherapy trials.246 The mean effect size for no-
treatment/waiting list response was 0.37.247 Thus, the effect size for placebo “effect” was 0.79 
(effect size for placebo response (1.16) minus effect size for no treatment). The authors conclude 
that half of the response to active drug is due to the placebo “effect”, one quarter is attributable to 
nonspecific factors, and only one quarter can be attributed to the administration of the active 
drug.248 
The authors proceed to arguing that the superiority of drug over placebo might be caused not 
by the drugs having true pharmacological effects that alleviate depression, but because they act as 
“active placebos”, causing more side effects than placebo pills. The argument is based on the 
observation that there is an exceptionally high correlation between drug and placebo responses, and 
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that medications not conventionally considered antidepressants were found as effective as 
antidepressants.249  
 The second meta-analysis that Kirsch bases his argument on, Kirsch & Moore 2002, uses 
data submitted to the FDA for approval of fluoxetine, paroxetine, sertraline, venlafaxine, 
nefazodone, and citalopram.250 Publication bias does not affect this data, since all trials submitted to 
the FDA were obtained using the Freedom of Information Act.251 In nine trials, there was missing 
data.252 
 All trials assessed depression severity on the Hamilton scale, and with the exception of one 
trial on mild depression, patients in all trials were either moderately or severely depressed (range of 
mean Hamilton scores 21.0 – 29.7).253  
 Weighted mean improvement scores were recorded for all trials, which had full data: these 
were the trials on fluoxetine, venlafaxine, and nefazodone.254 For these medications, the mean 
difference in improvement was 1.80 points on the Hamilton scale. Placebo response was 82 per cent 
of the drug response. The superiority of the active drugs over placebo was statistically significant.255 
 There were twelve fixed-dose studies included, whilst in most of the trials, dose was 
determined individually within a predetermined range. To assess the possible effect of dosage, last 
observation carried forward data was compared for patients receiving the lowest and highest 
prescribed doses in the fixed-dose studies. Mean improvement on the lowest dose was 9.57 points, 
and 9.97 points on the highest dose; this difference was not statistically significant.256 
 Kirsch & Moore note that the mean drug/placebo difference, 1.80 on the Hamilton scale, is 
of questionable clinical relevance. However, they point out that mean improvement in the placebo 
group was equal to or superior to improvement in the drug group in only four trials, and placebo 
was not significantly superior to drug in any of the trials. They concede that it is possible that there 
is a small but real drug effect, but go on to present the “active placebo” argument as another 
possible explanation. 257 Kirsch & Moore refer to the same Rabkin et al. 1986 study that Kirsch 
references in The Emperor’s New Drugs as evidence that the ability of doctors and patients to guess 
whether the patient has been assigned to the drug or placebo arm of a double-blind trial exceeds 
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chance.258 They also propose the more frequent side effects caused by drug rather than placebo 
administration as an explanation for this ability to guess,259 but ignore the fact that the Rabkin et al. 
1986 data lends no weight to this thesis, as I will discuss in section 4.  
They also discuss the possibility that drug and placebo effects are not additive. An 
assumption of placebo-controlled trials is that the drug response is the sum of the true 
pharmacological effect of the drug and the placebo response. In this case, the difference between 
drug and placebo response represents the “true” drug effect. If, however, these effects are not 
additive in this way, the drugs might be more effective than they seem, because the methodology of 
the trials is inadequate. Kirsch & Moore note that placebo alcohol and placebo caffeine are not fully 
additive in their effects when compared to the real thing. They propose a “balanced placebo design” 
for drug trials to sort out these effects; a full discussion is beyond the scope of this essay.260 
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3. “Active placebo” 
Both Kirsch and Moncrieff argue that the modest superiority of antidepressants over placebo is not 
due to a true pharmacological effect, but rather to patients breaking blind because of side effects of 
the active drug. This is the “active placebo” argument. Another aspect of the argument is the 
observation that other drugs, such as antipsychotic agents, benzodiazepines, and mood stabilizers, 
that are not conventionally considered antidepressants, have been found to be superior to placebo in 
treating depression. Since these drugs are supposedly not antidepressants, the critics argue, their 
superiority over placebo in treating depression stems from their side effects. The implication that 
the critics draw from this is that it demonstrates that conventional antidepressants, such as SSRIs, 
have no specific effect on depression, either. The superiority they demonstrate over placebo is due 
to the same reason as the superiority of other drugs over placebo in treating depression: the 
unwanted side effects they produce.  
Another aspect of this argument that Moncrieff in particular emphasizes is the idea that even 
though antidepressants have no specific pharmacological effect on depression, they have unspecific 
effects, such as sedation, which in certain situations can be useful in alleviating the symptoms from 
which the depressed patient suffers. 
 
3.1 “Active placebo”: Kirsch 
Kirsch argues that in double-blind trials, patients’ expectations of getting better are tempered by 
their knowledge that it is possible that they have been given a placebo. Breaking blind, according to 
Kirsch, leads to a change of expectations. If patients know they are taking placebo, they are less 
likely to think they are getting better, and if they know they are on the active drug, this enhances 
their expectation of recovery. This expectation, Kirsch maintains, affects recovery.261  
Kirsch writes that the only reason he can think of why such side effects of antidepressant 
medication as insomnia, diarrhea or nausea might be correlated with the alleviation of depression is 
that they lead the patient to break blind.262 Kirsch also writes: “the correlation between side effects 
and improvement is so strong as to be almost perfect.”263  
 Kirsch refers to the 2008 Sneed et al. study as evidence for his position.264 Sneed et al. 2008 
compared the response of patients in trials comparing different antidepressants with each other with 
the response of patients in placebo-controlled trials. The authors refer to Krell et al. 2004 in 
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pointing out that patients who have higher expectations of responding to treatment tend to improve 
better than patients whose expectations are more modest.265 They point out that patients in 
comparator trials know they are receiving a medication that is supposed to be effective. In placebo-
controlled trials, patients can only hope to receive such medication, and the doubt that they may end 
up receiving dummy pills potentially dampens their response to antidepressants.266 
 The Sneed et al. 2008 meta-analysis included 16 trials studying the treatment of acute-phase 
unipolar major depression in patients 60 years or older. Seven trials were placebo-controlled and 
nine were comparator trials.267 The drugs studied were escitalopram, fluoxetine, paroxetine, 
citalopram, venlafaxine, sertraline, nortriptyline, doxepin, imipramine, clomipramine, trimipramine, 
mirtazapine and bupropion.268 The primary outcome was response, defined in most trials as a 50% 
reduction in Hamilton score, but in two trials as 50% reduction in MADRS score and in three trials 
as a CGI score of one or two.269 In comparator trials, the odds of being a responder were 1.82 times 
higher than in placebo-controlled trials. They estimated the response rate as 60% in comparator 
trials and 46% in placebo-controlled trials.270 
Kirsch argues that this difference in response rates stems from the patients in the drug 
comparator trials knowing that they were definitely receiving an active drug, thus enhancing their 
expectations of recovery.271 Sneed et al. 2008 agrees that this is a possible interpretation of the 
results. The authors refer to Schweizer et al. 1998 and note that when patients suffering from such 
ailments as chronic pain, anxiety and Parkinson’s disease are unaware that they are being given 
treatment, they do not respond as well as when they know treatment is being administered.272 They 
also point out that it is possible that the observed differences stem from study doctors having 
different expectations in different types of trials, and raise the possibility that patients in placebo-
controlled trials might be more severely depressed than patients in comparator trials, which might 
affect response rates.273 
 Kirsch further points out that there is a correlation between experiencing side effects from 
SSRIs and experiencing improvement. He refers to Greenberg et al. 1994 as evidence.274 This is a 
meta-analysis of all placebo-controlled fluoxetine trials published through 1992. Thirteen trials 
                                                
265 ibid., 66. 
266 ibid., 66. 
267 ibid., 67. 
268 ibid., 68. 
269 ibid., 68. 
270 ibid., 70. 
271 Kirsch 2009, 17. 
272 Sneed, Rutherford & Rindskopf et al. 2008, 70. 
273 ibid., 71. 
274 Greenberg RP, Bornstein RF, Zborowski MJ et al. A meta-analysis of fluoxetine outcome in the treatment 
of depression. Journal of Nervous and Mental Disease 1994; 182: 547-551. 
39 
were included.275 The overall Cohen’s d effect size for fluoxetine was .40, which the authors 
consider moderate.276 They point out that the average patient taking fluoxetine was better off than 
two thirds of patients on placebo, noting that the results were quite reliable: it would take more than 
200 unpublished trials with zero effect size to render the results statistically nonsignificant.277  
 The authors did not find significant correlations between effect size and patients’ mean age, 
percentage of women, or fluoxetine dosage.278 However, effect size was significantly correlated 
with the proportion of patients reporting side effects.279 This was true both for clinician and patient 
reported outcomes. It should be noted, though, that only half of the studies provided data on side 
effects.280 The authors speculate on the same conclusion that Kirsch does: that the correlation 
between side effects and effect size is due to unblinding. Greenberg et al. also argue that trials with 
“active placebo” comparators might lend weight to the unblinding hypothesis.281  
Kirsch argues that one would expect the correlation to go in the opposite direction: that the 
unwanted side-effects of SSRIs, such as sexual dysfunction, insomnia and gastrointestinal distress 
would cause the patient to be more depressed, not less. He maintains that the reason that patients 
experiencing side effects show superior drug responses to those not experiencing side effects must 
be that those effects lead the patient to realize they are in the active treatment group.282  
 Kirsch argues that the 2009 paper by Barbui, Cipriani and Kirsch provides further evidence 
for his position. The aim of the study was to isolate the true pharmacological effect from possible 
“active placebo” effects. The study is an analysis of all published and unpublished trials conducted 
by GlaxoSmithKline on paroxetine. According to Kirsch 2009, it concludes that adjusting for 
drug/placebo differences in side effects eliminates the statistical significance of drug/placebo 
differences in efficacy.283 I was unable to find the Cipriani, Barbui & Kirsch paper on PubMed in 
January 2017. Kirsch lists it as unpublished in 2009. Presumably it is still unpublished, making it 
impossible to assess its relevance. 
 There is also some evidence that patients and doctors in supposedly double-blind trials are 
able to guess which treatment the patient is receiving, thus breaking blind. Kirsch points to Rabkin 
et al. 1986, which investigated this question.284 The study investigated patients’ and doctors’ 
guesses on assignment to treatment group in a randomized double-blind trial comparing 
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impipramine, phenelzine and placebo. 137 patients were assigned to either one of the drug arms or 
the placebo arm of the trial after a ten-day placebo washout.285 The patients included met Research 
Diagnostic Criteria for major, minor or intermittent depression. After six weeks of treatment, 
doctors and patients were asked to guess what treatment the patient had been assigned to. The 
patients’ response to this question was categorized as either active drug or placebo, whereas the 
doctors’ guesses for the specific active drugs were recorded separately. 
The study found that 79% of patients were able to correctly identify whether they were in 
the drug or the placebo arm of the study. Doctors could do this in 87% of cases.286 Patients 
receiving the active drug were more likely to guess their group correctly. 87% of patients on 
imipramine, 96% of patients on phenelzine, but only 59% of patients in the placebo group did so.287 
Kirsch points out that the likelihood of the patients randomly guessing correctly is exceedingly 
small.288 
 Kirsch goes on to point out studies comparing antidepressants with “active placebos”, i.e. 
drugs, which produce side effects but should have no pharmacological effect on depression. The 
aim of using such drugs as “placebo” is to prevent patients from breaking blind.289 Kirsch refers to 
Moncrieff et al. 2005 here in discussing nine antidepressant trials that used atropine as an “active 
placebo”. This study is a Cochrane Review based on virtually the same material as the 1998 
Moncrieff, Wessely & Hardy paper. There is slight variation in the results290, but for my purposes, 
the discussion I present on the 1998 paper in section 4.2 suffices. 
 A further aspect of the active placebo argument is that there is some evidence that active 
drugs, which are not antidepressants, are superior to placebo in the treatment of depression. In the 
1998 Kirsch & Sapirstein study, four active drugs that are not antidepressants are included. These 
are amylobarbitone, lithium, liothyronine, and adinazolam.291 Amylobarbitone is a barbiturate, an 
older class of sedative. Lithium is used as a mood stabilizer in bipolar illness. Liothyronine is a 
synthetic thyroid hormone used for hypothyreosis, and adinazolam is a benzodiazepine, a newer 
class of anxiolytic.292 The drug/placebo difference in effect size for these non-antidepressants when 
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given for depression was 0.76, whereas the effect size for the SSRIs, the drugs of choice for 
depression today, was 0.74.293 
The paper suggests that it is possible that these drugs have an indirect effect on depression, 
but in this case, it would be expected that they would not be as effective as antidepressants 
supposed to have a more specific effect. In fact, there is no difference in superiority over placebo 
between antidepressants and these other active drugs. The paper also suggests that perhaps these 
four drugs should be classified as antidepressants, but then the definition would need to be based 
merely on superiority over placebo in clinical trials rather than the underlying pharmacological 
mechanism.294  
However, the explanation that Kirsch and Sapirstein embrace in this paper is the same one 
Kirsch presents in The Emperor’s New Drugs: that the non-antidepressant active drugs are superior 
to placebo in the treatment of depression because they cause more side effects than placebo. I.e., the 
antidepressants and the other active drugs are more effective because patients realize they are 
receiving active treatment as a consequence of side effects.295  
 
3.2 Moncrieff on antidepressants versus “active placebo” 
One line of argument that Moncrieff pursues is that antidepressants seem less effective when they 
are compared to “active placebos” than when the comparator is an inert placebo. By definition a 
placebo is inert, but what Moncrieff means by “active placebo” is a substance that is not supposed 
to have any pharmacological effect on the disorder being studied, but which is sufficiently active 
pharmacologically that it produces some of the unwanted effects of the active drug being studied. 
Such “active placebos” should reduce the chance of unblinding. 
 In chapter nine of The Myth of the Chemical Cure, Moncrieff discusses a 1998 meta-
analysis of trials using an “active placebo” that she co-authored.296 The Moncrieff, Wessely & 
Hardy study included nine trials comparing imipramine, amitriptyline, and nortriptyline, all TCAs, 
with atropine. The trials were published between 1961-1984, with only one trial published in the 
1980s.297 A variety of outcomes for calculating effect size were used.298 The authors note that two of 
the trials demonstrated a statistically significant superiority of drug over atropine.299 In most trials, 
the results favored the antidepressant, but most results were not statistically significant.300  
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Moncrieff points out that in trials with inpatients, no statistically significant differences 
between drug and “active placebo” were found, and “only small differences” were observed in all 
but one of the trials involving outpatients.301 She notes that results still favored the antidepressants, 
and that the quality of the trials has rightly been questioned, but maintains that even the use of 
atropine as “active placebo” was not sufficient to maintain the integrity of the blind.302 
 In two trials, there was an attempt to assess the integrity of the blind by asking assessors to 
guess to which treatment arm patients had been randomized. The authors state that “[…] the 
guesses were more accurate than would be predicted by chance,” even though they note that the 
effect was not statistically significant.303 The authors note that in the Weintraub & Aronson 1963 
trial, raters assessed patients who they guessed to be in the drug arm to be more improved. 
Moncrieff argues in The Myth of the Chemical Cure that this suggests that assessments of patients 
may have been influenced by treatment expectations.304 Moncrieff and colleagues also point out that 
in the Hollister et al. 1964 trial, more side effects were reported in the drug group despite the use of 
atropine as an “active placebo”, which means that “residual unblinding effects may have 
occurred”.305 Moncrieff argues that this is evidence of the possibility that the use of atropine was 
insufficient for maintaining the integrity of the blind.306 
 The authors refer to other meta-analyses and point out that their results show more modest 
efficacy for antidepressants than other studies.307 This suggests that the use of an “active placebo” 
yields more modest results for antidepressants.  
 
3.3 Moncrieff on antidepressants versus other drugs 
Moncrieff’s placebo argument is not limited to pointing out the limited superiority of 
antidepressants over placebo. An important aspect of it is her claim that drugs other than those 
considered specifically antidepressants have been found to be superior to placebo in the treatment 
of depression in clinical trials. Moncrieff notes that in the 1960s, when benzodiazepines were new, 
many trials found them to be equivalent or superior to antidepressants for depression, but in the 
1970s most trials found antidepressants superior. She points out that when the new benzodiazepine 
alprazolam arrived on the market in the 1980s, trials found it effective for treating depression.308 
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In The Myth of the Chemical Cure, she presents a table summarizing the results of seventeen 
trials or reviews of various drugs versus either an established antidepressant or placebo for treating 
depression. These studies were published between 1955-2006, most of them having been published 
before 1990. The drugs studied range from benzodiazepines and antipsychotics to amphetamine-
derivatives and opioids.309 
Davies & Shepherd 1955 found the antihypertensive/antipsychotic drug reserpine superior 
to placebo for treating depression. The 1982 Robertson & Trimble review of antipsychotics for 
depression found antipsychotics superior to placebo and in most comparisons equivalent with 
antidepressants. Blashki et al. 1971 found amylobarbitone broadly as effective as amitriptyline. 
Schatzberg & Cole 1978 reviewed 20 trials comparing benzodiazepines with antidepressants; in 
half benzodiazepines were either equal to antidepressants or superior to placebo. Imlah 1985, 
Feighner et al. 1983, Rickels et al. 1987, and Weissman et al. 1992 found alprazolam superior to 
placebo and at least equal to imipramine or amitriptyline.310  
Rickels et al. 1970 found pemoline, a stimulant now withdrawn from the market, and 
metylphenidate, a stimulant used for treating ADHD, superior to placebo. Hare et al. 1964 found a 
combination of dexamphetamine and amylobarbitone equal in efficacy as imipramine. Robinson et 
al. 1990 found buspirone, indicated for treating anxiety, superior to placebo for treating depression. 
Fabre 1990 found a trend favoring buspirone over placebo. Emrich et al. found buprenorphine, a 
strong opioid, superior to placebo for depression. Philipp et al. 1999, Szegedi et al. 2005, and 
Kasper et al. 2006 found the medicinal herb St. John’s wort equivalent to imipramine and 
paroxetine and superior to placebo.311  
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4. Assessing the Kirsch-Moncrieff argument 
In the previous two sections, I have attempted to present the major evidence that the Kirsch-
Moncrieff arguments are based on. The aim here is to ask the central question of this essay: how 
does the evidence and argumentation stand up to scrutiny?  
 
4.1 Short-term treatment 
The fundamental problem with Moncrieff’s argument about the lack of efficacy of antidepressants 
for short-term treatment is the limited amount of relevant evidence. To be sure, Moncrieff amasses 
an impressive number of trials in support of her argument, but a close reading of the relevant 
section of her book shows that there are only two studies that really matter here: Kirsch et al. 2002 
and NICE 2004. 
The value of the 1965 Medical Research Council study for Moncrieff’s argument is 
questionable, as it concerns early antidepressants no longer in clinical use. Likewise, the 1975 
National Institutes of Mental Health study has virtually no relevance for our discussion of the claim 
that antidepressants in clinical use today are no better than placebo. Again, the 1976 Bielski & 
Friedel review concerns tricyclic antidepressants, so it is of limited value in assessing Moncrieff’s 
argument as it relates to the SSRIs and other modern antidepressants. The same goes for the Joyce 
& Paykel review, published in 1989. All these studies may have value in understanding how the 
notion of an antidepressant was constructed historically. To be fair to Moncrieff, this is partly what 
she is doing, and understanding this construction is part of her overall project. 
The other studies referred to in this section of The Myth of the Chemical Cure illustrate her 
point that older meta-analyses show antidepressants to be more effective than newer ones. I have 
discussed some of the newer ones. Bech et al. 2000, Khan, Warner & Brown 2000, and Storosum et 
al. 2001 show modest superiority of drug over placebo. Moncrieff does not dispute this. 
Thus, in this section, Moncrieff is really left with only Kirsch 2002 and NICE 2004 to make 
the argument that antidepressants are so ineffective that the drug effect is virtually irrelevant. 
Moncrieff asserts that the 1.7-point superiority of drug over placebo in the Kirsch et al 2002 study 
is clinically meaningless by “all assessments of clinical validity.”312 She gives no justification for 
this claim, and gives no indication of which assessments of clinical validity she is referring to, 
though, to be sure, the difference of 1.7 points would be clinically irrelevant under the NICE 
criteria. Unfortunately, I am unable to give any analysis of the other crucial study, the NICE 2004 
review. 
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I have been critical of Moncrieff in this section, but I think this is the part of the argument 
that stands up to scrutiny, though Moncrieff is not very convincing in making her case. At least on 
the basis of the material covered in this essay, it seems clear that the effectiveness of 
antidepressants is modest. In virtually all the trials covered, the superiority of drug over placebo 
amounts to only a few points on a particular rating scale. I am fully aware that I am not using any 
rigorous criteria in claiming this, but rather making a general observation. Furthermore, whether 
this moderate superiority, however defined, makes a clinically relevant difference, is another 
question, which I will briefly return to in the Conclusion. 
 
4.2 Severity 
As we have seen, Moncrieff moves from criticizing the evidence on acute phase treatment to 
arguing against the commonly held assumption that antidepressants are more effective in treating 
more severe forms of depression. This part of her argument is undermined by her disingenuous use 
of the evidence.  
 Again, part of the problem here is Moncrieff’s use of old studies. A couple of the studies she 
refers to – Bielski & Friedel 1976 and Joyce & Paykel 1989 – do not really even demonstrate the 
lack of efficacy of antidepressants in more severe depression, they merely point out that the 
evidence is unclear. The Angst et al. 1993 study that Moncrieff notes found weak and mostly not 
statistically significant effects for greater drug efficacy in more severe depression, studied only one 
antidepressant, moclobemide versus placebo and TCAs.313 
Moncrieff muddles the waters even further with her rhetoric on the 2002 Khan et al. study. 
It seems that she considers a problem the fact that full data was available only for so-called 
investigational antidepressants. She fails to mention that these antidepressants are some of the most 
common in clinical use today – and much more relevant than older TCAs such as imipramine that 
she relies on to make much of her argument. To be sure, it is a weakness of Khan et al. 2002 that 
the authors do not name the “established” antidepressants; I assume that they mean the same older 
antidepressants (imipramine, amitriptyline, and trazodone) investigated in Khan et al. 2000.314  
In any case, these “investigational” antidepressants are the most clinically relevant today. 
Moncrieff notes that the relationship of initial severity of depression with drug response appeared to 
be weaker for the established antidepressants,315 but this is almost irrelevant.  
Moncrieff’s use of the Walsh et al. 2002 study is likewise disingenuous. Referring to this 
study, she writes: “… one recent meta-analysis found no effect of initial severity on treatment 
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response.”316 What she fails to mention is that the study did not primarily investigate the question 
that she is discussing. Walsh et al. 2002 is not a study of how the initial severity of depression 
affects drug response or drug/placebo differences, it is a study concerned with how placebo 
responses have changed over the years.317 The effect of the initial severity of depression on SSRI 
response was not even investigated. Moncrieff’s enlistment of this study in support of her argument 
that antidepressants have limited efficacy in severe depression is dubious. 
Moncrieff’s arguments about psychotic depression and bipolar illness are also curious. She 
utilizes the Kocsis et al. 1990 paper in arguing that the general ineffectiveness of antidepressants 
rather than the presence of psychotic symptoms explains the apparent lack of efficacy of 
antidepressants in treating psychotic depression. This should be taken with a number of caveats. 
First, like most of the studies that Moncrieff draws on, this study examines tricyclic antidepressants, 
not SSRIs or other more recent drugs most widely in use today. Second, the number of patients 
included was small: there were only 25 patients in the psychotic group.318  
Furthermore, Kocsis et al. 1990 included both patients diagnosed with unipolar depression 
and bipolar disorder.319 Given that these are two distinct diagnostic categories, it is possible that 
there are differences between unipolar depression and a depressive episode in bipolar illness, which 
confound the results. Furthermore, it should be noted that, even if Kocsis et al. 1990 could be 
construed as lending some weight to Moncrieff’s particular argument about the relationship 
between depression severity and drug response, it does not seem to support her more general 
argument about the effectiveness of antidepressants, since 67% of moderately depressed patients 
responded well to active drug treatment.320 
Moncrieff’s use of the Sachs et al. 2007 study to make her argument does not stand up to 
scrutiny, either. Again, Moncrieff discusses a study whose primary objective was to answer a 
different question than the one necessary to make her point. The study investigated the use of 
adjunct antidepressant treatment in the depressive phase of bipolar illness rather than the effect of 
the severity of depression on drug/placebo differences.321 And again, Moncrieff bases her argument 
on an assumption, and does not provide the actual figures on severity in this trial. The baseline data 
is available322, but since the study investigated a different outcome, the authors have not analyzed 
the potential effect of depression severity on drug/placebo differences in outcome.  
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In Sachs et al. 2007, the average baseline severity of depression on the MADRS scale is 
24.5 in the drug group and 24.0 in the placebo group.323 The maximum result on the MADRS scale 
is 60 points. According to Jääskeläinen & Miettunen 2011, a score of 24 would indicate mild 
depression and a score of 25 would indicate moderate depression.324 Thus, the figures on severity in 
Sachs et al. 2007 are not even compatible with Moncrieff’s claim that bipolar depression is worse 
than unipolar depression. I by no means wish to dispute that in general, depression is more severe 
for those suffering from bipolar disorder, but merely to point out the problematic way that 
Moncrieff develops her argument. 
 As I have already noted, it is also possible that there is something different about depression 
in bipolar disorder, which causes it to react differently to medication than unipolar depression. It is 
quite questionable to draw conclusions about the efficacy of treatments by assuming that diagnosis 
makes no difference. Furthermore, all participants in Sachs et al. 2007 were on mood stabilizers. 
Such drugs are used for unipolar depression only in special cases. It is hard to justify Moncrieff’s 
enlistment of Sachs et al. 2007 as evidence for her argument.   
 
4.3 Long-term treatment 
We have seen that Moncrieff wishes to undermine the evidence on maintenance treatment with 
antidepressants, as well. Discontinuation of antidepressant treatment can cause withdrawal 
effects.325 The 2004 NICE guideline notes that “All patients prescribed antidepressants should be 
informed that, although the drugs are not associated with tolerance and craving, 
discontinuation/withdrawal symptoms may occur on stopping, missing doses or, occasionally, on 
reducing the dose of the drug.”326  
Moncrieff argues that withdrawal effects undermine the evidence base on relapse prevention 
studies, since it is not possible to distinguish them from actual recurrence of depression. Whilst it is 
completely possible that this is true, Moncrieff is not able to prove her point. She refers to only 
Viguera et al. 1998 in making this argument. As we have seen, the study showed clear superiority 
for drug over placebo. The results are completely compatible with Moncrieff’s thesis, but as the 
authors point out, they are also compatible with the conventional view that antidepressants have a 
real prophylactic effect.327 
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Moncrieff argues that people who attribute their recovery to drugs will feel “anxious and 
vulnerable” when the drugs are withdrawn, but she provides no evidence for this claim.328 Whatever 
its factual basis, it should be noted that if applied to the Viguera et al. 1998 meta-analysis, it 
assumes that patients know they have been withdrawn. In 25 of the trials, patients were withdrawn 
to placebo. Thus, Moncrieff assumes that they have been unblinded, presumably due to withdrawal 
symptoms, since this is the only way they would know that they were now receiving placebo 
instead of the active drug they had been taking until then. However, Viguera et al. 1998 did not 
study such symptoms. 
Moncrieff also maintains that psychological effects are probably more important for 
explaining the increased risk of relapse after withdrawal than the pharmacological stress 
hypothesized by Viguera et al. 1998.329 She gives no evidence for this position, nor does she give a 
definition of psychological dependence, presumably distinct from the physiological dependence 
resulting in withdrawal symptoms. But she also seems to assume that it is an established fact that 
people who have been stabilized on antidepressants for longer are at greater risk of relapse when 
treatment is withdrawn. To be sure, the relapse rates in such patients were higher in Viguera et al. 
1998, but this result was not statistically significant, and Moncrieff provides no further evidence for 
her assumption. 
 
4.4 “Active placebo” 
There are three aspects of the “active placebo” argument I have discussed: the correlation between 
side effects and response, the effectiveness of drugs other than “antidepressants” in treating 
depression, and the evidence from antidepressant trials utilizing “active placebos”. How do they 
stand up to scrutiny? 
Kirsch maintains that he cannot think of any other reason beside unblinding that would 
explain the correlation between such unwanted side-effects of antidepressant use as gastrointestinal 
distress and insomnia and alleviation of depression.330 This is disingenuous. There is another 
possible explanation for this correlation that is noted in Greenberg et al. 1994, one of the studies 
that Kirsch utilizes in making his case. The patients who are predisposed to respond to the 
therapeutic effects of the drugs might be similarly physiologically predisposed to experience side 
effects.331 Kirsch ignores this possibility, even though it is as compatible with the data as the 
unblinding hypothesis is.  
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Kirsch also makes a strong claim about the correlation between response to medication and 
side effects being almost perfect.332 There is evidence of such a correlation, but Kirsch goes too far 
in stating that the correlation is almost perfect. Since the implications are so significant, such a 
claim should be backed up with a wealth of evidence. However, Kirsch gives only a single 
reference for his claim, the same Greenberg et al. 1994 study of one antidepressant, fluoxetine.333 
The Rabkin et al. 1986 study is crucial to the “active placebo” argument, as it demonstrated 
that the ability of doctors and patients to guess whether patients have been assigned to drug or 
placebo treatment in a double-blind trial exceeds chance. This evidence is important for assessing 
such trials in general, but Kirsch ignores the full implications of the study for the particular 
argument that he is making.  
Rabkin et al. 1986 not only investigated the ability to guess, but also some factors that 
correlated with this ability. They found that for patients, assignment to active drug treatment and 
treatment response were associated with greater accuracy in guessing.334 Doctors guessed more 
accurately for patients that did not respond to placebo than for placebo responders, and for those 
that responded to imipramine than those who did not.335  
Crucially for Kirsch’s argument, Rabkin et al. 1986 also investigated the association 
between side effects and guessing accuracy. Data on these was available for only 57% of patients. 
Events were considered side effects only if they had not been reported at the start of the trial.336 The 
authors did not find any evidence that side effects had an impact on patients’ guesses of their 
assignment to active drug or placebo.337 Kirsch ignores this. The data on side effects in this trial is 
limited, but this is the one trial that actually investigated the crucial question for the “active 
placebo” argument: whether the premise that more frequent side effects lead patients to break blind 
is correct. And the data does not support the Kirsch-Moncrieff argument that more frequent side 
effects in active drug groups enable patients to guess they are receiving an active drug, thus 
inflating their expectations.338  
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The second aspect of the “active placebo” argument that I discussed was the evidence from 
using “active” rather than inert placebos as comparators in antidepressant trials. The idea here was 
that the use of “placebos” that produce side effects should protect blinding, and therefore trials 
utilizing such a design would yield more modest results for antidepressant efficacy. 
 The one study that Moncrieff presents as evidence for this argument, the 1998 Moncrieff, 
Wessely & Hardy meta-analysis, is problematic for a number of reasons. Firstly, the trials are old. 
The newest one was published in 1984, the others between 1961-1975. All trials are of TCAs.339 As 
Moncrieff herself points out, the trials are of questionable quality.340  
Most importantly, it is dubious whether one can draw implications in support of the Kirsch-
Moncrieff “active placebo” argument from this study. To really make the argument, one should be 
able to demonstrate that the premise of the argument is correct. The premise is that experiencing 
side effects leads people to guess they are in the drug group. Both Moncrieff and Kirsch seem to 
treat this premise as obviously true, but it is not. I have already shown how the data from the one 
trial that explicitly addressed this issue, Rabkin et al. 1986, in no way lends credence to this 
premise. 
The Moncrieff, Wessely & Hardy 1998 meta-analysis does not provide any evidence for this 
premise. Moncrieff makes much of the fact that in one trial, more side effects were reported in the 
drug group.341 However, there is no data on whether there was any correlation between side effects 
and guessing; guessing treatment group was not studied. Furthermore, Moncrieff fails to mention in 
The Myth of the Chemical Cure that even though there were two trials that did assess guessing 
treatment group, and the guesses, according to her, exceeded chance342, this result was not 
statistically significant.343 Not reaching statistical significance here means, by definition, that the 
guesses did not exceed chance.344 Patients’ guesses were not even assessed.  
Both Kirsch and Moncrieff attempt to bolster their “active placebo” argument by 
maintaining that drugs other than conventional antidepressants are as effective in treating 
depression as SSRIs, SNRIs, and TCAs.  It is not possible to delve into the pharmacology of these 
drugs here, or to survey the literature for evidence of their effectiveness in depression, but I want to 
offer a couple of tentative criticisms of their conclusions.  
As regards lithium, it does not seem surprising that it was superior to placebo, given that it is 
indicated for bipolar illness, and that it is used as an adjunct for treatment of treatment-resistant 
depression. Perhaps lithium’s mood-stabilizing effect caused an amelioration of depressive 
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symptoms. Whether lithium should be called an antidepressant or merely a “mood stabilizer” is 
another question; I cannot consider this here. The point is merely to point out that there are other 
possible, perhaps even reasonable explanations of the data besides the Kirsch-Moncrieff hypothesis. 
Kirsch’s argument here is based on the assumption that drugs such as the SSRIs are 
considered antidepressants because mainstream psychiatry maintains that they have a specific effect 
on the underlying pathophysiology of depression – they affect serotonin levels in the synapse – and 
that by this criterion, lithium is not an antidepressant, because it does not affect serotonin.  
 It is also not surprising that barbiturates and benzodiazepines would be superior to placebo 
for the treatment of depression. They might produce pleasant effects in patients, which might be 
experienced as an alleviation of depression, even if they had no specific effect on the monoamine 
system. Moncrieff’s reference to a trial showing alprazolam superior to placebo is particularly 
striking. Given how addictive alprazolam is known to be, it would be quite surprising if it did not 
produce pleasant effects which patients found more effective in alleviating depression than placebo. 
The same can be said for buprenorphine, another drug that Moncrieff refers to in this context. 
The concept of an antidepressant is intimately linked with how depression is defined. My 
discussion here is necessarily a mere sketch, since a deeper conceptual analysis of how depression 
should be understood is beyond the scope of this essay. 
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Conclusion 
On the basis of the evidence discussed in this essay, the statistical superiority of antidepressants 
over placebo is not in doubt. In all the meta-analyses cited here, and in almost all individual trials, 
active drugs fare better than placebo. It would be difficult to disagree with the guidelines’ claim that 
the effect size of antidepressants is consistent. 
However, it is also difficult to dispute the critics’ general placebo argument that the 
superiority of drug over placebo is modest. In the evidence cited here, patients on drug treatment 
tend to improve by a few more points on the various scales compared to those taking placebo.  
 This makes the issue of clinical relevance crucial. The critics argue that though the drugs 
show statistical superiority, this is of doubtful relevance clinically. They refer to NICE criteria on 
clinical relevance in making this point. Unfortunately, I was unable to access the full NICE 
guideline, so it is not possible to assess how NICE came to define a particular cut off point for 
relevance. The critics themselves do not present any evidence on why relevance should be defined 
in a particular way. It is curious that since both Moncrieff and Kirsch repeatedly refer to the NICE 
criteria, they give no indication of why they consider the criteria so authoritative. We are left with 
anecdotal argument and pure assertion.  
 The guidelines also refer to clinical relevance. They argue that antidepressants have 
clinically relevant effectiveness even in mild depression. However, we have seen that the guidelines 
make dubious claims about mild depression based on meta-analyses that do not study mild 
depression. Furthermore, the guidelines do not directly comment on the clinical relevance of 
antidepressants in more severe depression. They merely assert that antidepressant treatment 
becomes more important as the severity of depression grows. The guidelines do not give any 
definition of clinical relevance. On this crucial issue, we are left in the lurch by both sides of the 
debate. 
 We have seen how the critics attempt to explain the modest superiority of drug over placebo 
with the “active placebo” argument. Both Kirsch and Moncrieff maintain that the greater incidence 
of side effects in active drug treatment groups unblinds patients, and thus changes their expectations 
of recovery. However, we have seen that the critics are unable to prove this argument. Especially 
for Kirsch, the Rabkin et al. 1986 study is central to the argument. We have seen that this study 
lends no weight to the unblinding hypothesis. On the basis of the material the critics present, it is 
neither possible to prove or disprove the hypothesis. Another hypothesis – that patients who are 
predisposed to benefit from drug treatment are also predisposed to experience unwanted effects – is 
at least as compatible with the evidence as the Kirsch-Moncrieff unblinding hypothesis. 
 Whereas Kirsch focuses on acute treatment, Moncrieff also argues that antidepressants are 
ineffective for long-term maintenance treatment. The guidelines maintain that antidepressants are 
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clearly superior to placebo for preventing relapse. On this issue, it is not possible to come to a 
definitive conclusion based on the evidence cited here. It is possible that the superiority of drug 
over placebo seen in the maintenance studies cited by the guidelines is a true drug effect. However, 
Moncrieff’s argument that greater rate of relapse for patients taking placebo is due to withdrawal 
effects is also compatible with the data. 
 Moncrieff argues that even though antidepressants are widely prescribed today, outcomes 
for depressed patients remain poor.345 A fundamental problem with the literature reviewed here is 
that it is almost completely focused on depression scores on a particular rating scale, i.e. on what 
symptoms patients report, or on assessments made by doctors, rather than on how depressed 
individuals do in real life. In their discussion of antidepressant effectiveness, the guidelines do not 
include a single study on how antidepressant treatment affects any real-world outcome, such as 
ability to maintain or resume employment. To be sure, in the section giving guidance on suicidal 
behavior, they do include one reference to a study showing a correlation between the rise in 
antidepressant prescriptions and a fall in the suicide rate.346  
Moncrieff critically discusses some of the evidence on suicide in the Myth of the Chemical 
Cure.347 She also points out some studies suggesting that episodes of depression last longer for 
patients taking antidepressants, and that people taking medication are less likely to return to 
work.348 Assessing these arguments is left for further study, but I would suggest that such outcomes, 
rather than an arbitrary cut-off point on a rating scale assessing symptoms, would be central for a 
meaningful definition of clinical relevance. 
 The individual clinician facing the individual patient suffering from depression has to make 
the decision whether to prescribe. As the guidelines point out, placebo is a tool used in clinical 
trials, not a treatment option in clinical practice.349 To be sure, there are a variety of other treatment 
options, such as psychotherapy, which are not covered in this essay. But considering only the 
simplified choice of whether to prescribe an antidepressant, I believe that the evidence covered here 
overall supports the use of drug treatment, if the patient is motivated to try it. Patient motivation is, 
of course, important in virtually any kind of medical treatment, but perhaps here it is more 
important still, since the weighing of benefits and risks is perhaps trickier than with some common 
treatments in other fields of medicine. Average response to drug, while better than average placebo 
response, is modest. The drugs have unwanted effects, and patients may experience withdrawal 
effects from prolonged use. It is also possible, though by no means proven, that there are subgroups 
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of patients who are both predisposed to respond better to drugs and experience more unwanted 
effects. 
We have seen that there is a consistent statistical superiority of drugs over placebo. This 
represents the average, so the individual may respond better – or, of course, worse. Given all of this, 
an antidepressant can still make a difference for the individual patient, even if most of their 
response is due to non-specific effects.  
Both Kirsch and Moncrieff employ the language of myth in making their case. Moncrieff 
maintains that psychiatry is beset by the “myth of the chemical cure” – the myth that psychiatric 
disorders are primarily biochemical imbalances to be corrected by applying chemicals. Kirsch 
called his book The Emperor’s New Drugs, implying that underneath all the pomp and circumstance 
of drug marketing, the emperor has no clothes – the drugs do not do much. Both seem to imply that 
a myth means an untruth.  
A myth is not true in the strictest sense, and may be used for malicious purposes, but a myth 
can also embody something essential. It can perhaps distill an important truth into a more 
memorable or understandable form. In the case of psychiatry, there is little doubt that the “myth of 
the chemical cure” has been misused in marketing antidepressants. But perhaps it contains a kernel 
of truth – not that psychiatric disorders are reducible to imbalances in brain chemicals, but that 
biochemical treatments do have a role in helping people afflicted by such maladies.  
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